10586814

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 3	NOV 26	MARPAT enhanced with FSORT command
NEWS 4	NOV 26	CHEMSAFE now available on STN Easy
NEWS 5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS 6	DEC 01	ChemPort single article sales feature unavailable
NEWS 7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS 9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 14	FEB 10	COMPENDEX reloaded and enhanced
NEWS 15	FEB 11	WTEXTILES reloaded and enhanced
NEWS 16	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants

```
 NEWS 25  MAR 11  ESBIOBASE reloaded and enhanced
 NEWS 26  MAR 20  CAS databases on STN enhanced with new super role
                  for nanomaterial substances
 NEWS 27  MAR 23  CA/CAplus enhanced with more than 250,000 patent
                  equivalents from China

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:49:06 ON 26 MAR 2009

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 09:49:22 ON 26 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   24 MAR 2009  HIGHEST RN 1126602-40-1
DICTIONARY FILE UPDATES:  24 MAR 2009  HIGHEST RN 1126602-40-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.
```

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10586814.str



chain nodes :
7 8 9 10 11 12 13 14 15
ring nodes :
1 2 3 4 5 6
chain bonds :
5-7 7-8 8-9 9-10 10-11 10-14 11-12 11-15 12-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
10-14 11-15 12-13
exact bonds :
5-7 7-8 8-9 9-10 10-11 11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 09:49:35 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      761 TO ITERATE

100.0% PROCESSED      761 ITERATIONS                              30 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        13565 TO    16875
PROJECTED ANSWERS:             272 TO      928

L2           30 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 09:49:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    15084 TO ITERATE

100.0% PROCESSED    15084 ITERATIONS                             651 ANSWERS
SEARCH TIME: 00.00.01

L3          651 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10586814a.str
```



chain nodes :
7 8 9 10 11 12 13 14
ring nodes :
1 2 3 4 5 6 16 17 18 19 20 21
chain bonds :
5-7 7-8 8-9 9-10 10-11 10-13 11-12 11-14 12-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21
exact/norm bonds :
10-13 11-14 12-16 16-17 16-21 17-18 18-19 19-20 20-21
exact bonds :
5-7 7-8 8-9 9-10 10-11 11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 16 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l4
SAMPLE SEARCH INITIATED 09:53:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 34 TO ITERATE

100.0% PROCESSED 34 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 331 TO 1029
PROJECTED ANSWERS: 1 TO 80

L5 1 SEA SSS SAM L4

=> s l4 sss full
FULL SEARCH INITIATED 09:53:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 818 TO ITERATE

100.0% PROCESSED 818 ITERATIONS 30 ANSWERS
SEARCH TIME: 00.00.01

L6 30 SEA SSS FUL L4

=> FIL HCAPLUS
COST IN U.S. DOLLARS SINCE FILE ENTRY 374.64 TOTAL SESSION 374.86
FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 09:54:00 ON 26 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 26 Mar 2009 VOL 150 ISS 13
FILE LAST UPDATED: 24 Mar 2009 (20090324/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3
L7 10 L3

=> s l6

```
L8            3 L6

=> s l7 and py<=2004
      25139514 PY<=2004
L9            4 L7 AND PY<=2004

=> s l8 and py<=2004
      25139514 PY<=2004
L10           0 L8 AND PY<=2004

=> d l8 ibib abs hitstr tot

L8   ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2008:467208  HCAPLUS
DOCUMENT NUMBER:          148:472388
TITLE:                    Preparation of amino alcohol derivatives as renin
                          inhibitors
INVENTOR(S):              Herold, Peter; Mah, Robert; Marti, Christiane
PATENT ASSIGNEE(S):       Speedel Experimenta AG, Switz.
SOURCE:                   Eur. Pat. Appl., 39pp.
                          CODEN: EPXXDW
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     EP 1911762            A1    20080416    EP 2006-121768          20061004
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
             BA, HR, MK, RS
PRIORITY APPLN. INFO.:                       EP 2006-121768          20061004
OTHER SOURCE(S):          MARPAT 148:472388
GI
```



I

```
AB   The invention relates to substituted amino alcs.
     Q-NHCH(CH2CR2R3CH2-T)CH(CH2-X)O-Z [Q is H, a radical A whereby an amide
```

bond is formed, or CO2CHR6OCOR7; T is R1, R1CO, or R1CONR5; X is NR5COR4, -alkylene-CONR4R5, or NR8R9; Z is H or a radical A whereby an ester bond is formed; R1 is aryl or nitrogen-containing heterocyclyl; R2, R3 are H or alkyl or together are cycloalkyl; R4 is (un)substituted alkyl, whereby hydroxy groups are optionally substituted by a radical A forming an ester bond; R5 is H or alkyl; R6 is optionally carboxy- or hydroxy-substituted alkyl or arylalkyl; R7 is alkyl; NR8R9 is a ring; A is a mono- or dipeptidic residue of one or two of the 20 natural amino acids; a radical A is present in at least one of R4, Q or Z or at least Q is a group of formula CO2CHR6OCOR7] or their pharmaceutically-acceptable salts, including a process for their preparation and use as medicines, in particular as renin inhibitors. The enzymic substrate portion of the compound is simultaneously a substrate for a membrane transporter. Thus, amino acid derivative I bis(trifluoroacetate) was prepared by a multistep sequence involving amide and ester forming reactions.

IT 1020111-83-4P 1020111-85-6P 1020111-86-7P
RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino alc. derivs. as renin inhibitors)

RN 1020111-83-4 HCAPLUS

CN Butanamide, 2-amino-N-[(1S,3S)-1-[(1S)-1-hydroxy-2-(1-piperidinyl)ethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-3-methyl-, (2S)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 1020111-82-3
CMF C30 H53 N3 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1020111-85-6 HCAPLUS
CN L-Valinamide, glycyl-N-[(1S,3S)-1-[(1S)-1-hydroxy-2-(1-piperidinyl)ethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 1020111-84-5
CMF C32 H56 N4 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1020111-86-7 HCAPLUS
CN Propanoic acid, 2-methyl-, 1-[[[[(1S,3S)-1-[(1S)-1-hydroxy-2-(1-piperidinyl)ethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]amino]carbonyl]oxy]ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 861922-24-9
RL: PRPH (Prophetic); RCT (Reactant); RACT (Reactant or reagent)
(preparation of amino alc. derivs. as renin inhibitors)
RN 861922-24-9 HCAPLUS
CN 1-Piperidineethanol, α-[(1S,3S)-1-amino-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



IT 861901-06-6P 1020112-22-4P 1020112-23-5P
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino alc. derivs. as renin inhibitors)
RN 861901-06-6 HCAPLUS
CN Carbamic acid, N-[(1S,3S)-1-[(1S)-1-hydroxy-2-(1-piperidinyl)ethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1020112-22-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1020112-23-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:81037 HCAPLUS
DOCUMENT NUMBER: 146:162906
TITLE: phenylalkyldiaminoalcohols for treatment of Alzheimer's disease, malaria, or HIV infection.
INVENTOR(S): Herold, Peter; Stutz, Stefan; Tschinke, Vincenzo; Stojanovic, Aleksandar; Marti, Christiane; Quirmbach, Michael; Schumacher, Christoph
PATENT ASSIGNEE(S): Speedel Experimenta AG, Switz.
SOURCE: Eur. Pat. Appl., 22pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1745778	A2	20070124	EP 2006-117468	20060719
EP 1745778	A3	20070307		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
US 20070021413	A1	20070125	US 2006-488854	20060719

PRIORITY APPLN. INFO.: CH 2005-1209 A 20050720
OTHER SOURCE(S): MARPAT 146:162906
GI



I

AB Use of title compds. [I; R = 1-4 of H, halo, alkyl, cycloalkyl, polyhaloalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, hydroxyalkyl, alkylthioalkyl, imidazolylthioalkyl, etc.; R1 = H, OH, amino, (substituted) alkyl, cycloalkyl, alkanoyl, alkoxycarbonyl, aralkyl, heterocyclylalkyl; R2 = (substituted) alkyl, cycloalkyl, alkylsulfonyl, cycloalkylsulfonyl, aralkylsulfonyl, alkanoyl, alkoxycarbonyl, aralkyl, etc.; R1R2N = (substituted) (unsatd.) 4-8 membered heterocyclyl; R3, R4 = H, alkyl, alkoxycarbonyl, alkanoyl; R5 = H, alkyl; CR5R5 = C3-8 cycloalkylidene; R6 = H, OH], for the preparation of a medication for the inhibition of β-secretase, cathepsin D, plasmepsin II, and/or HIV protease, is claimed (no data).
IT 861899-68-5 861899-69-6 861899-70-9
861899-78-7 861899-79-8 861899-81-2
861900-70-1 1057086-85-7 1057086-89-1
1069117-68-5 1069117-69-6
RL: PRPH (Prophetic)
(phenylalkyldiaminoalcohols for treatment of Alzheimer's disease, malaria, or HIV infection.)
RN 861899-68-5 HCAPLUS
CN 1-Piperidineethanol, α-[(1S,3S)-1-amino-3-[[4-methoxy-3-(3-

methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, hydrochloride (1:2), (αS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861899-69-6 HCAPLUS
CN 2-Piperidinone, 1-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861899-70-9 HCAPLUS
CN 1-Piperidineethanol, α-[(1S,3S)-1-amino-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-2,6-dimethyl-, hydrochloride (1:2), (αS,2R,6S)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861899-78-7 HCAPLUS
CN 1-Piperidineethanol, α-[(1S,3S)-1-amino-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-2-methyl-, hydrochloride (1:2), (αS,2S)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861899-79-8 HCAPLUS
CN 1-Piperidineethanol, α-[(1S,3S)-1-amino-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-2-methyl-, hydrochloride (1:2), (αS,2R)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861899-81-2 HCAPLUS
CN 1-Piperidineethanol, α-[(1S,3S)-1-amino-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-4-methyl-, hydrochloride (1:2), (αS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861900-70-1 HCAPLUS
CN 2-Piperidinone, 1-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,3-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1057086-85-7 HCAPLUS
CN 1-Piperidineethanol, α-[(1S,3S)-1-amino-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-3-methyl-, hydrochloride (1:2), (αS,3S)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 1057086-89-1 HCAPLUS
CN 1-Piperidineethanol, α-[(1S,3S)-1-amino-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-3-methyl-, hydrochloride (1:2), (αS,3R)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 1069117-68-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1069117-69-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:696868 HCAPLUS
DOCUMENT NUMBER: 143:193798
TITLE: Preparation of diamino alcohols as renin inhibitors
INVENTOR(S): Herold, Peter; Stutz, Stefan; Stojanovic, Aleksandar; Tschinke, Vincenzo; Marti, Christiane; Quirmbach, Michael
PATENT ASSIGNEE(S): Speedel Experimenta A.-G., Switz.
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005070877	A1	20050804	WO 2005-EP50272		20050121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2553831	A1	20050804	CA 2005-2553831		20050121
EP 1735270	A1	20061227	EP 2005-701590		20050121
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR					
CN 1910141	A	20070207	CN 2005-80002920		20050121
BR 2005007067	A	20070612	BR 2005-7067		20050121
JP 2007522123	T	20070809	JP 2006-550176		20050121
IN 2006DN04188	A	20070713	IN 2006-DN4188		20060720
US 20070161622	A1	20070712	US 2006-586814		20060724
PRIORITY APPLN. INFO.:			CH 2004-94	A	20040123
			WO 2005-EP50272	W	20050121

OTHER SOURCE(S): CASREACT 143:193798; MARPAT 143:193798
GI



I



II

AB Title compds. I [R1 = H, OH, NH2, etc.; R2 = (un)substituted alkyl, cycloalkyl, alkylsuphonyl, etc. or R1 and R2 together can form with the nitrogen atom that they are attached to a (un)saturated, (un)substituted 4-8 membered heterocycle containing an addnl. N, O or S, etc.; R3 = H, alkoxycarbonyl, alkanoyl, etc.; R4 = H, alkyl, alkoxycarbonyl, etc.; R5 independently = H, alkyl or together cycloalkylidene; R6 = H or OH; R = H, halo, alkoxyalkyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as renin inhibitors. Thus, e.g., II was prepared by coupling of tert-butyl{3(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-4-methyl-1(S)-(R)-oxiranylpentyl}-carbamate (preparation given) with piperidine and subsequent deprotection. The activity of I was evaluated in vitro monitoring the reduction of the formation of angiotensin I in different systems (no data). I as renin inhibitor should prove useful in the treatment of hypertension, heart failure and glaucoma. Pharmaceutical compns. comprising I are disclosed.

IT 861899-68-5P 861899-69-6P 861899-70-9P
861899-78-7P 861899-79-8P 861899-80-1P
861899-81-2P 861900-70-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diamino alcs. as renin inhibitors)

RN 861899-68-5 HCAPLUS

CN 1-Piperidineethanol, α-[(1S,3S)-1-amino-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, hydrochloride (1:2), (αS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861899-69-6 HCAPLUS
CN 2-Piperidinone, 1-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861899-70-9 HCAPLUS
CN 1-Piperidineethanol, α-[(1S,3S)-1-amino-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-2,6-dimethyl-, hydrochloride (1:2), (αS,2R,6S)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861899-78-7 HCAPLUS
CN 1-Piperidineethanol, α-[(1S,3S)-1-amino-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-2-methyl-, hydrochloride (1:2), (αS,2S)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861899-79-8 HCAPLUS
CN 1-Piperidineethanol, α-[(1S,3S)-1-amino-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-2-methyl-, hydrochloride (1:2), (αS,2R)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861899-80-1 HCAPLUS
CN 1-Piperidineethanol, α-[(1S,3S)-1-amino-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-3-methyl-, hydrochloride (1:2), (αS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861899-81-2 HCAPLUS
CN 1-Piperidineethanol, α-[(1S,3S)-1-amino-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-4-methyl-, hydrochloride (1:2), (αS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861900-70-1 HCAPLUS
CN 2-Piperidinone, 1-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,3-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 861901-06-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of diamino alcs. as renin inhibitors)
RN 861901-06-6 HCAPLUS
CN Carbamic acid, N-[(1S,3S)-1-[(1S)-1-hydroxy-2-(1-piperidinyl)ethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l9 ibib abs hitstr tot

L9 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:472477 HCAPLUS
DOCUMENT NUMBER: 139:52753
TITLE: Preparation of substituted hydroxyethylamines as β-secretase inhibitors
INVENTOR(S): Tenbrink, Ruth; Maillard, Michel; Warpehoski, Martha
PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company
SOURCE: PCT Int. Appl., 306 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003050073	A1	20030619	WO 2002-US39050	20021206 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2469622	A1	20030619	CA 2002-2469622	20021206 <--
AU 2002360508	A1	20030623	AU 2002-360508	20021206 <--
US 20040044072	A1	20040304	US 2002-313849	20021206 <--
US 7312360	B2	20071225		
EP 1453788	A1	20040908	EP 2002-795769	20021206 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002014736	A	20041123	BR 2002-14736	20021206 <--
JP 2005511735	T	20050428	JP 2003-551100	20021206

MX 2004005428	A	20041206	MX 2004-5428		20040604 <--
US 20080096942	A1	20080424	US 2007-962454		20071221
PRIORITY APPLN. INFO.:			US 2001-338452P	P	20011206
			US 2002-313849	A1	20021206
			WO 2002-US39050	W	20021206

OTHER SOURCE(S): MARPAT 139:52753
GI



I



II

AB Title compds. I [E = bond, alkylene; RA = H, benzyloxycarbonyl; RD = H, alkoxycarbonyl; K = (un)substituted alkyl; A = aryl, cycloalkyl, heteroaryl, etc.; W = bond, SO0-2, (un)substituted amino; L = bond, absent, etc.; G = absent, alkyl, cycloalkyl, etc.; R2-3 = H, alkyl, aryl, etc.; RN = Ph naphthyl, tetralinyl, etc.; RC = heteroaryl, etc.] are prepared as β-secretase inhibitors. For instance, N-[(1S,2R)-1-[3-(cyclohexylmethyl)benzyl]-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl]acetamide (II) isolated as the HCl salt is prepared in several steps. The key intermediate in the synthesis is derived from the asym. hydrogenation of Me 2-[[(benzyloxy)carbonyl]amino]-3-(2-bromophenyl)acrylate (preparation given) to give the corresponding phenylalanine analog intermediate. I are useful for the treatment of Alzheimer's disease.

IT 546115-61-1P 546115-62-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted hydroxyethylamines as β-secretase inhibitors)

RN 546115-61-1 HCAPLUS

CN Carbamic acid, [(1S)-1-[(1R)-2-[[1-(3-bromophenyl)cyclopropyl]amino]-1-hydroxyethyl]-3-methyl-4-phenylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546115-62-2 HCAPLUS
CN Acetamide, N-[(1S)-1-[(1R)-2-[[1-(3-bromophenyl)cyclopropyl]amino]-1-hydroxyethyl]-3-methyl-4-phenylbutyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:11099 HCAPLUS
DOCUMENT NUMBER: 136:69597
TITLE: Synthesis of hydrazide and α-alkoxyamide angiogenesis inhibitors
INVENTOR(S): Craig, Richard A.; Kawai, Megumi; Lynch, Linda M.; Patel, Jyoti R.; Sheppard, George S.; Wang, Jieyi; Yang, Fan; Ba-Maung, Nwe
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 78 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020002152	A1	20020103	US 2001-833917	20010412 <--

US 20040167126 A1 20040826 US 2004-782502 20040219 <--
US 6887863 B2 20050503
PRIORITY APPLN. INFO.: US 2000-197262P P 20000414
US 2001-833917 A1 20010412
OTHER SOURCE(S): MARPAT 136:69597
GI



I



II



III

AB Title compds. I [R1 = alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, (heterocycle)alkyl, R5S-alkylene; R3 = H, alkyl, arylalkyl; R4 = NR6R7, OR8; R5 = alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl; R6-7 = H, alkanoyl, alkenyl, alkenyloxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, alkyl, alkylthioalkyl, aryl, arylalkanoyl, etc.; or R6-7 together are arylalkylidene; or R6-7 together with the nitrogen atom to which they are attached, form a heterocycle; R8 = H, alkanoylalkyl, alkenyl, alkoxycarbonylalkyl, alkyl, amidoalkyl, aryl, arylalkyl, etc.; R9-10 = H, alkyl, aryl] were prepared Over 450 synthetic examples were reported. For instance, (2R)-2-(Boc)amino-3-cyclohexylpropanoic acid was reduced to the corresponding alc. (PhMe, Red-Al, 0°C, room temperature 1 h) and oxidized to II (DMSO, Py•SO3, Et3N, room temperature 30 min). II was converted to the bisulfite addition product (H2O, NaHSO3, 5°C, 24 h) and reacted with KCN to give the α-hydroxy nitrile intermediate which was hydrolyzed to the carboxylic acid (12 N HCl, reflux, 21 h) and converted to III by condensation with benzylhydrazine (DCM/DMA, DIC, NMM, HOBt). Selected compds. I had IC50 < 0.1 μM for MetAP2. I are useful for inhibiting angiogenesis.

IT 369360-46-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; synthesis of hydrazide and α-alkoxyamide angiogenesis inhibitors)

RN 369360-46-3 HCAPLUS

CN Benzenehexanoic acid, β-amino-α-hydroxy-, 2-(3-chlorobenzoyl)hydrazide, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:780840 HCAPLUS
DOCUMENT NUMBER: 135:331197
TITLE: Synthesis of hydrazide and α-alkoxyamide angiogenesis inhibitors
INVENTOR(S): Craig, Richard A.; Kawai, Megumi; Lynch, Linda M.; Patel, Jyoti R.; Sheppard, George S.; Wang, Jieyi; Yang, Fan; Ba-Maung, Nwe Y.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079157	A1	20011025	WO 2001-US12274	20010413 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2406442	A1	20011025	CA 2001-2406442	20010413 <--
EP 1272456	A1	20030108	EP 2001-925029	20010413 <--
EP 1272456	B1	20041027		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001007204	A	20040225	BR 2001-7204	20010413 <--
JP 2004509063	T	20040325	JP 2001-576759	20010413 <--
AT 280753	T	20041115	AT 2001-925029	20010413 <--
PT 1272456	T	20050228	PT 2001-925029	20010413
ES 2231475	T3	20050516	ES 2001-925029	20010413
MX 2002010082	A	20030425	MX 2002-10082	20021011 <--
HK 1053825	A1	20050819	HK 2003-104469	20030620

PRIORITY APPLN. INFO.:	US 2000-549995	A	20000414
	US 2001-813008	A	20010321
	WO 2001-US12274	W	20010413

OTHER SOURCE(S): MARPAT 135:331197

GI



I



II



III

AB Title compds. I [R1 = alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, (heterocycle)alkyl, R5S-alkylene; R3 = H, alkyl, arylalkyl; R4 = NR6R7, OR8; R5 = alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl; R6-7 = H, alkanoyl, alkenyl, alkenyloxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, alkyl, alkylthioalkyl, aryl, arylalkanoyl, etc.; or R6-7 together are arylalkylidene; or R6-7 together with the nitrogen atom to which they are attached, form a heterocycle; R8 = H, alkanoylalkyl, alkenyl, alkoxycarbonylalkyl, alkyl, amidoalkyl, aryl, arylalkyl, etc.; R9-10 = H, alkyl, aryl] were prepared Over 450 synthetic examples were reported. For instance, (2R)-2-(Boc)amino-3-cyclohexylpropanoic acid was reduced to the corresponding alc. (PhMe, Red-Al, 0°C, room temperature 1 h) and oxidized to II (DMSO, Py•SO3, Et3N, room temperature 30 min). II was converted to the bisulfite addition product (H2O, NaHSO3, 5°C, 24 h) and reacted with KCN to give the α-hydroxy nitrile intermediate which was hydrolyzed to the carboxylic acid (12 N HCl, reflux, 21 h) and converted to III by condensation with benzylhydrazine (DCM/DMA, DIC, NMM, HOBt). Selected compds. I had IC50 < 0.1 μM for MetAP2. I are useful for inhibiting angiogenesis.

IT 369360-46-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; synthesis of hydrazide and α-alkoxyamide angiogenesis inhibitors)

RN 369360-46-3 HCAPLUS

CN Benzenehexanoic acid, β-amino-α-hydroxy-, 2-(3-chlorobenzoyl)hydrazide, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:604555 HCAPLUS
DOCUMENT NUMBER: 125:301563
ORIGINAL REFERENCE NO.: 125:56459a,56462a
TITLE: Design and synthesis of novel, pseudo C2 symmetric inhibitors of HIV protease
AUTHOR(S): Hanessian, Stephen; Devasthale, Patrick V.
CORPORATE SOURCE: Department Chemistry, Universite Montreal, Montreal, QC, H3C 3J7, Can.
SOURCE: Bioorganic & Medicinal Chemistry Letters (1996), 6(18), 2201-2206
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A novel series of chain-extended, pseudo C2 sym. 1,5-diamino alc. analogs was designed and synthesized using an efficient nitroaldol condensation mediated by triethylsilyl triflate and TBAF.xH2O. Thus, derivs. of the nitro compound I, e.g., II and III were prepared Prototypical acyclic compds. harboring a central spirolactam or a nitro group, and amide variants of an off-center 1,5-diamino alc. analog were synthesized and their activities against HIV protease evaluated.

IT 182937-11-7P 182937-20-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(design and synthesis of pseudo C2 sym. inhibitors of HIV protease)

RN 182937-11-7 HCAPLUS
CN Benzenepentanol, δ-[bis(phenylmethyl)amino]-α-[1-[bis(phenylmethyl)amino]-2-phenylethyl]-β-nitro- (9CI) (CA INDEX NAME)



RN 182937-20-8 HCAPLUS
CN Carbamic acid, [2-hydroxy-3-nitro-1,5-bis(phenylmethyl)-1,5-pentanediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



=> d l7 ibib abs hitstr tot

L7 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:467208 HCAPLUS
DOCUMENT NUMBER: 148:472388
TITLE: Preparation of amino alcohol derivatives as renin inhibitors
INVENTOR(S): Herold, Peter; Mah, Robert; Marti, Christiane
PATENT ASSIGNEE(S): Speedel Experimenta AG, Switz.
SOURCE: Eur. Pat. Appl., 39pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1911762	A1	20080416	EP 2006-121768	20061004
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
PRIORITY APPLN. INFO.:			EP 2006-121768	20061004

OTHER SOURCE(S): MARPAT 148:472388
GI



I

AB The invention relates to substituted amino alcs. Q-NHCH(CH2CR2R3CH2-T)CH(CH2-X)O-Z [Q is H, a radical A whereby an amide bond is formed, or CO2CHR6OCOR7; T is R1, R1CO, or R1CONR5; X is NR5COR4, -alkylene-CONR4R5, or NR8R9; Z is H or a radical A whereby an ester bond is formed; R1 is aryl or nitrogen-containing heterocyclyl; R2, R3 are H or alkyl or together are cycloalkyl; R4 is (un)substituted alkyl, whereby hydroxy groups are optionally substituted by a radical A forming an ester bond; R5 is H or alkyl; R6 is optionally carboxy- or hydroxy-substituted alkyl or arylalkyl; R7 is alkyl; NR8R9 is a ring; A is a mono- or dipeptidic residue of one or two of the 20 natural amino acids; a radical A is present in at least one of R4, Q or Z or at least Q is a group of formula CO2CHR6OCOR7] or their pharmaceutically-acceptable salts, including a process for their preparation and use as medicines, in particular as renin inhibitors. The enzymic substrate portion of the compound is simultaneously a substrate for a membrane transporter. Thus, amino acid derivative I bis(trifluoroacetate) was prepared by a multistep sequence involving amide and ester forming reactions.

IT 1020111-88-9P
RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino alc. derivs. as renin inhibitors)

RN 1020111-88-9 HCAPLUS

CN L-Valine, trans-4-[2-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-1,1-dimethyl-2-oxoethyl]cyclohexyl ester, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 1020111-87-8
CMF C35 H61 N3 O7

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 861901-11-3
RL: PRPH (Prophetic); RCT (Reactant); RACT (Reactant or reagent)
(preparation of amino alc. derivs. as renin inhibitors)
RN 861901-11-3 HCAPLUS
CN Carbamic acid, N-[(1S,3S)-1-[(1S)-2-amino-1-hydroxyethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 1020112-24-6P
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino alc. derivs. as renin inhibitors)
RN 1020112-24-6 HCAPLUS
CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-, trans-4-[2-[[(2S,3S,5S)-3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-1,1-dimethyl-2-oxoethyl]cyclohexyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

OMe

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:353219 HCAPLUS
DOCUMENT NUMBER: 148:379345
TITLE: Preparation of nitrate esters of aryl or heterocyclyl aminodiols as cardiovascular agents.
INVENTOR(S): Herold, Peter; Mah, Robert; Marti, Christiane; Jotterand, Nathalie
PATENT ASSIGNEE(S): Speedel Experimenta AG, Switz.
SOURCE: PCT Int. Appl., 72pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008031811	A1	20080320	WO 2007-EP59504	20070911

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: CH 2006-1453 A 20060912

OTHER SOURCE(S): MARPAT 148:379345

AB R1YCH2CR2R3CH2CH(NH2)CH(OH)CH2XVZnONO2 [R1 = substituted aryl, heterocyclyl; R2, R3, R4 = H, alkyl; CR2R3 = cycloalkyl; V = A, AOA, arylene, cycloalkylene, etc.; X = NR4CO, ACONR4; A = alkylene; Y = bond, CO, CONR4; Z = Z1U; Z1 = O2C, OCO2; U = (substituted) A, phenylene, etc.; n = 0, 1], were prepared Title compds. inhibited renin with IC50 values in the range of 0.1-100 nM.

IT 1013922-21-8P 1013922-26-3P 1013923-18-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrate esters of aryl or heterocyclyl aminodiols as cardiovascular agents)

RN 1013922-21-8 HCAPLUS

CN Cyclohexaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-4-(nitrooxy)-, trans- (CA INDEX NAME)

Absolute stereochemistry.



RN 1013922-26-3 HCAPLUS

CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methyl-2-(nitrooxy)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1013923-18-6 HCAPLUS

CN Carbamic acid, N-[(1S,3S)-1-[(1S)-1-hydroxy-2-[[2-methyl-2-(nitrooxy)-1-oxopropyl]amino]ethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-

methylpentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 861901-11-3
RL: PRPH (Prophetic); RCT (Reactant); RACT (Reactant or reagent)
(preparation of nitrate esters of aryl or heterocyclyl aminodiols as cardiovascular agents)
RN 861901-11-3 HCAPLUS
CN Carbamic acid, N-[(1S,3S)-1-[(1S)-2-amino-1-hydroxyethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 1013923-11-9P
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nitrate esters of aryl or heterocyclyl aminodiols as cardiovascular agents)
RN 1013923-11-9 HCAPLUS
CN Carbamic acid, N-[(1S,3S)-1-[(1S)-1-hydroxy-2-[[2-methyl-2-[trans-4-(nitrooxy)cyclohexyl]-1-oxopropyl]amino]ethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:1237245 HCAPLUS
DOCUMENT NUMBER: 147:502091
TITLE: Preparation of 1-heterocyclylamino-2-hydroxy-3-amino-ω-arylalkanes as renin inhibitors for treating hypertension and other renin-mediated diseases
INVENTOR(S): Baldwin, John J.; Claremon, David A.; Dillard, Lawrence W.; Ishchenko, Alexey V.; Yuan, Jing; Xu, Zhenrong; McGeehan, Gerard; Zeng, Wenguang
PATENT ASSIGNEE(S): Vitae Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 89pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007123718	A1	20071101	WO 2007-US7961	20070330

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-787936P P 20060331
OTHER SOURCE(S): MARPAT 147:502091
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB 1-Heterocyclylamino-2-hydroxy-3-amino-ω-arylalkanes of formula I (wherein R1,R3 is H, halogen, cyano, etc.; R2 is H, (C1-C12)alkyl, etc.; R2 and R3 together can also be part of a ring; R4 is H, lower alkyl, hydroxy, etc.; X is methylene or hydroxymethylene; R5 is lower alkyl, lower haloalkyl,etc.; R6 is amino, lower alkylamino, etc.; R7 is H, lower alkyl, etc.; Q is a an oxothiadiazole or a cyclobutenedione; R8 is lower alkyl, lower haloalkyl,etc.)the salts thereof have renin-inhibiting properties and can be used as antihypertensive, medicinally active ingredients. Methods for preparing the compds. are disclosed. Example compound II was prepared by reacting 3,4-dimethoxycyclobut-3-ene-1,2-dione with a methoxybenzyl heptan-3-carbamate to give III, which was subsequently reacted with benzylamine and deprotected. The compds. of the invention exhibited inhibiting activities in in vitro renin inhibition assays at min. concns. of from approx. 5 + 10-5 M to approx. 10-12 M.

IT 955020-80-1P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(benzylamino)cyclobut-3-ene-1,2-dione 955020-84-5P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(benzylamino)cyclobut-3-ene-1,2-dione hydrochloride 955020-85-6P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-aminocyclobut-3-ene-1,2-dione 955020-86-7P , 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(methylamino)cyclobut-3-ene-1,2-dione 955020-87-8P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(ethylamino)cyclobut-3-ene-1,2-dione 955020-88-9P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(propylamino)cyclobut-3-ene-1,2-dione 955020-89-0P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(cyclopropylmethyl)amino]cyclobut-3-ene-1,2-dione 955020-90-3P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(butylamino)cyclobut-3-ene-1,2-dione 955020-91-4P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(isobutylamino)cyclobut-3-ene-1,2-dione 955020-92-5P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(2-methoxyethyl)amino]cyclobut-3-ene-1,2-dione 955020-93-6P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(piperidin-1-yl)cyclobut-3-ene-1,2-dione 955020-94-7P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(2-cyclopropylethyl)amino]cyclobut-3-ene-1,2-dione 955020-95-8P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-morpholinocyclobut-3-ene-1,2-dione 955020-96-9P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(neopentylamino)cyclobut-3-ene-1,2-dione 955020-97-0P 955020-98-1P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(tert-pentylamino)cyclobut-3-ene-1,2-dione 955020-99-2P 955021-01-9P 955021-02-0P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(isopentylamino)cyclobut-3-ene-1,2-dione

955021-03-1P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(pentylamino)cyclobut-3-ene-1,2-dione 955021-04-2P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(N-butyl-N-methylamino)cyclobut-3-ene-1,2-dione 955021-05-3P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(2,2,2-trifluoroethyl)amino]cyclobut-3-ene-1,2-dione 955021-06-4P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(4-methylpiperazin-1-yl)cyclobut-3-ene-1,2-dione 955021-07-5P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(dipropylamino)cyclobut-3-ene-1,2-dione 955021-08-6P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(2-methylpentan-2-yl)amino]cyclobut-3-ene-1,2-dione 955021-09-7P 955021-10-0P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(hexylamino)cyclobut-3-ene-1,2-dione 955021-11-1P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(N-methyl-N-pentylamino)cyclobut-3-ene-1,2-dione 955021-12-2P, 3-[[(2R,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(N-methyl-N-pentylamino)cyclobut-3-ene-1,2-dione 955021-13-3P, 3-[[(2R,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(2-methylpentan-2-yl)amino]cyclobut-3-ene-1,2-dione 955021-14-4P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(cyclohexylmethyl)amino]cyclobut-3-ene-1,2-dione 955021-15-5P 955021-16-6P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(heptylamino)cyclobut-3-ene-1,2-dione 955021-17-7P 955021-18-8P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(2-methylhexan-2-yl)amino]cyclobut-3-ene-1,2-dione 955021-19-9P, 3-[[2-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-3,4-dioxocyclobut-1-enyl]amino]-2,2-dimethylpropanamide 955021-20-2P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(phenethylamino)cyclobut-3-ene-1,2-dione 955021-22-4P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(2-cyclohexylethyl)amino]cyclobut-3-ene-1,2-dione 955021-23-5P 955021-24-6P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(2,4,4-trimethylpentan-2-yl)amino]cyclobut-3-ene-1,2-dione 955021-25-7P , 3-[((1S,2R)-2-Phenylcyclopropyl)amino]-4-[[(2S,3S,5S)-5-[3-(3-methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]cyclobut-3-ene-1,2-dione 955021-26-8P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(2,3-dihydro-1H-inden-2-yl)amino]cyclobut-3-ene-1,2-dione 955021-27-9P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(3-phenylpropyl)amino]cyclobut-3-ene-1,2-dione 955021-28-0P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(N-methyl-N-phenethylamino)cyclobut-3-ene-1,2-dione 955021-29-1P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[2-

methylphenethylamino]cyclobut-3-ene-1,2-dione 955021-30-4P,
N-[3-[[2-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-3,4-dioxocyclobut-1-enyl]amino]-2,2-dimethylpropyl]acetamide 955021-31-5P 955021-34-8P,
3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(4-phenylbutyl)amino]cyclobut-3-ene-1,2-dione 955021-35-9P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(2,4-dimethylphenethyl)amino]cyclobut-3-ene-1,2-dione 955021-36-0P,
3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(2-chlorophenethyl)amino]cyclobut-3-ene-1,2-dione 955021-37-1P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(3-chlorophenethyl)amino]cyclobut-3-ene-1,2-dione 955021-39-3P,
3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(4-chlorophenethyl)amino]cyclobut-3-ene-1,2-dione 955021-42-8P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-(4-phenylpiperidin-1-yl)cyclobut-3-ene-1,2-dione 955021-46-2P,
3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(4-nitrophenethyl)amino]cyclobut-3-ene-1,2-dione 955021-48-4P 955021-49-5P,
3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(2,5-dimethoxyphenethyl)amino]cyclobut-3-ene-1,2-dione 955021-50-8P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(2,3-dimethoxyphenethyl)amino]cyclobut-3-ene-1,2-dione 955021-51-9P,
3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[(2,2,3,3,4,4,4-heptafluorobutyl)amino]cyclobut-3-ene-1,2-dione 955021-52-0P 955021-53-1P,
3-[N-[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]-N-methylamino]-4-(butylamino)cyclobut-3-ene-1,2-dione 955021-54-2P,
3-[N-[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]-N-methylamino]-4-(phenethylamino)cyclobut-3-ene-1,2-dione 955021-55-3P, 3-[[(2S,3S,5S)-5-(4-Methoxy-3-propoxybenzyl)-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[N-methyl-N-(2-methylpentan-2-yl)amino]cyclobut-3-ene-1,2-dione 955021-58-6P,
3-[[(2S,3S,5S)-5-(4-Methoxy-3-propoxybenzyl)-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[N-methyl-N-(2-methylpentan-2-yl)amino]cyclobut-3-ene-1,2-dione hydrochloride 955021-59-7P,
3-[[(2S,3S,5S)-5-(4-Methoxy-3-propoxybenzyl)-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[N-methyl-N-(2-methylhexan-2-yl)amino]cyclobut-3-ene-1,2-dione 955021-61-1P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-hexylcyclobut-3-ene-1,2-dione 955021-66-6P 955021-67-7P,
(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-1-[[1,1-dioxo-4-(phenethylamino)-1,2,5-thiadiazol-3-yl]amino]-3-amino-6-methylheptan-2-ol 955021-70-2P, (2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-1-[[1,1-dioxo-4-(phenethylamino)-1,2,5-thiadiazol-3-yl]amino]-3-amino-6-methylheptan-2-ol hydrochloride 955021-71-3P,
(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-1-[[4-(butylamino)-1,1-dioxo-1,2,5-thiadiazol-3-yl]amino]-3-amino-6-methylheptan-2-ol 955021-72-4P, (2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-1-[[4-(pentylamino)-1,1-dioxo-1,2,5-thiadiazol-3-yl]amino]-3-amino-6-methylheptan-2-ol 955021-73-5P,
3-[[(2S,3S,5S)-5-[3-(3-Methoxybenzyl)-4-methoxybenzyl]-3-amino-2-hydroxy-6-

methylheptyl]amino]-4-(ethylamino)cyclobut-3-ene-1,2-dione 955021-74-6P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[N-methyl-N-(2-methylpentan-2-yl)amino]cyclobut-3-ene-1,2-dione 955021-75-7P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-amino-2-hydroxy-6-methylheptyl]amino]-4-[N-methyl-N-(2-methylhexan-2-yl)amino]cyclobut-3-ene-1,2-dione
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 1-heterocyclylamino-2-hydroxy-3-amino-ω-arylalkanes as renin inhibitors for treating hypertension and other renin-mediated diseases)

RN 955020-80-1 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(phenylmethyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955020-84-5 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(phenylmethyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



RN 955020-85-6 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-amino-4-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955020-86-7 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-(methylamino)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 955020-87-8 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-(ethylamino)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 955020-88-9 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-(propylamino)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 955020-89-0 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(cyclopropylmethyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955020-90-3 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-(butylamino)- (CA INDEX NAME)

Absolute stereochemistry.



RN 955020-91-4 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(2-methylpropyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955020-92-5 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(2-methoxyethyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955020-93-6 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-(1-piperidinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 955020-94-7 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(2-cyclopropylethyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955020-95-8 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-(4-morpholinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 955020-96-9 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(2,2-dimethylpropyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955020-97-0 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(1-methylbutyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955020-98-1 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(1,1-dimethylpropyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955020-99-2 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(1,2-dimethylpropyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-01-9 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[[(2S)-2-methylbutyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-02-0 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(3-methylbutyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-03-1 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-(pentylamino)- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-04-2 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-(butylmethylamino)- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-05-3 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(2,2,2-trifluoroethyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-06-4 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-07-5 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-(dipropylamino)- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-08-6 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(1,1-dimethylbutyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-09-7 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(1-methylpentyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-10-0 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-(hexylamino)- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-11-1 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-(methylpentylamino)- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-12-2 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2R,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-(methylpentylamino)- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-13-3 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2R,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(1,1-dimethylbutyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-14-4 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(cyclohexylmethyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-15-5 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-(2-ethyl-1-piperidinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-16-6 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-(heptylamino)- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-17-7 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(1-methylhexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 955021-18-8 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(1,1-dimethylpentyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-19-9 HCAPLUS
CN Propanamide, 3-[[2-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 955021-20-2 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(2-phenylethyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-22-4 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(2-cyclohexylethyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-23-5 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(1-methylheptyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 955021-24-6 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(1,1,3,3-tetramethylbutyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

CMe3

RN 955021-25-7 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[[(1S,2R)-2-phenylcyclopropyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-26-8 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(2,3-dihydro-1H-inden-2-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-27-9 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(3-phenylpropyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-28-0 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[methyl(2-phenylethyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-29-1 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[[2-(2-methylphenyl)ethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-30-4 HCAPLUS
CN Acetamide, N-[3-[[2-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]-2,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-31-5 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-(3-phenyl-1-pyrrolidinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-34-8 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(4-phenylbutyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-35-9 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[[2-(2,4-dimethylphenyl)ethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-36-0 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[[2-(2-chlorophenyl)ethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-37-1 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[[2-(3-chlorophenyl)ethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-39-3 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[[2-(4-chlorophenyl)ethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-42-8 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-46-2 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[[2-(4-nitrophenyl)ethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-48-4 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[3-(phenylmethyl)-1-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-49-5 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[[2-(2,5-dimethoxyphenyl)ethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-50-8 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[[2-(2,3-dimethoxyphenyl)ethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-51-9 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(2,2,3,3,4,4,4-heptafluorobutyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 955021-52-0 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[[2-(4-morpholinyl)-2-(3-pyridinyl)ethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-53-1 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]methylamino]-4-(butylamino)- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-54-2 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]methylamino]-4-[(2-phenylethyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-55-3 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[(4-methoxy-3-propoxyphenyl)methyl]-6-methylheptyl]amino]-4-[(1,1-dimethylbutyl)methylamino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-58-6 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[(4-methoxy-3-propoxyphenyl)methyl]-6-methylheptyl]amino]-4-[(1,1-dimethylbutyl)methylamino]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 955021-59-7 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[(4-methoxy-3-propoxyphenyl)methyl]-6-methylheptyl]amino]-4-[(1,1-dimethylpentyl)methylamino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-61-1 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-hexyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-66-6 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-hexyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 955021-61-1
CMF C30 H48 N2 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 955021-67-7 HCAPLUS
CN Benzenepentanol, β-amino-α-[[[1,1-dioxido-4-[(2-phenylethyl)amino]-1,2,5-thiadiazol-3-yl]amino]methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-70-2 HCAPLUS
CN Benzenepentanol, β-amino-α-[[[1,1-dioxido-4-[(2-phenylethyl)amino]-1,2,5-thiadiazol-3-yl]amino]methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:1), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 955021-71-3 HCAPLUS
CN Benzenepentanol, β-amino-α-[[[4-(butylamino)-1,1-dioxido-1,2,5-thiadiazol-3-yl]amino]methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-72-4 HCAPLUS
CN Benzenepentanol, β-amino-α-[[[1,1-dioxido-4-(pentylamino)-1,2,5-thiadiazol-3-yl]amino]methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-73-5 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-

[(3-methoxyphenyl)methyl]phenyl]methyl]-6-methylheptyl]amino]-4-(ethylamino)- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-74-6 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(1,1-dimethylbutyl)methylamino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-75-7 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-4-[(1,1-dimethylpentyl)methylamino]- (CA INDEX NAME)

Absolute stereochemistry.



IT 955020-79-8, tert-Butyl [(2S,3S,5S)-5-[3-(3-methoxypropoxy)-4-methoxybenzyl]-2-hydroxy-6-methyl-1-(methylamino)heptan-3-yl]carbamate
955021-63-3, (2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-1,3-diamino-6-methylheptan-2-ol
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 1-heterocyclylamino-2-hydroxy-3-amino-ω-arylalkanes as renin inhibitors for treating hypertension and other renin-mediated diseases)

RN 955020-79-8 HCAPLUS
CN Carbamic acid, N-[(1S,3S)-1-[(1S)-1-hydroxy-2-(methylamino)ethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-,

1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-63-3 HCAPLUS
CN Benzenepentanol, β-amino-α-(aminomethyl)-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



IT 861901-11-3P, tert-Butyl [(2S,3S,5S)-5-[3-(3-methoxypropoxy)-4-methoxybenzyl]-1-amino-2-hydroxy-6-methylheptan-3-yl]carbamate 955020-81-2P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-(tert-butoxycarbonylamino)-2-hydroxy-6-methylheptyl]amino]-4-methoxycyclobut-3-ene-1,2-dione 955020-83-4P 955021-57-5P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-(tert-butoxycarbonylamino)-2-hydroxy-6-methylheptyl]amino]-4-[N-methyl-N-(2-methylpentan-2-yl)amino]cyclobut-3-ene-1,2-dione 955021-64-4P, 3-[[(2S,3S,5S)-5-[3-(3-Methoxypropoxy)-4-methoxybenzyl]-3-(tert-butoxycarbonylamino)-2-hydroxy-6-methylheptyl]amino]-4-hexylcyclobut-3-ene-1,2-dione 955021-68-8P, tert-Butyl [(2S,3S,5S)-5-[3-(3-methoxypropoxy)-4-methoxybenzyl]-1-[(1,1-dioxo-4-methoxy-1,2,5-thiadiazol-3-yl)amino]-2-hydroxy-6-methylheptan-3-yl]carbamate 955021-69-9P, tert-Butyl [(2S,3S,5S)-5-[3-(3-methoxypropoxy)-4-methoxybenzyl]-1-[[1,1-dioxo-4-(phenethylamino)-1,2,5-thiadiazol-3-yl]amino]-2-hydroxy-6-methylheptan-3-yl]carbamate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1-heterocyclylamino-2-hydroxy-3-amino-ω-arylalkanes as renin inhibitors for treating hypertension and other renin-mediated diseases)

RN 861901-11-3 HCAPLUS
CN Carbamic acid, N-[(1S,3S)-1-[(1S)-2-amino-1-hydroxyethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester

(CA INDEX NAME)

Absolute stereochemistry.



RN 955020-81-2 HCAPLUS
CN Carbamic acid, N-[(1S,3S)-1-[(1S)-1-hydroxy-2-[(2-methoxy-3,4-dioxo-1-cyclobuten-1-yl)amino]ethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 955020-83-4 HCAPLUS
CN Carbamic acid, N-[(1S,3S)-1-[(1S)-2-[[3,4-dioxo-2-[(phenylmethyl)amino]-1-cyclobuten-1-yl]amino]-1-hydroxyethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-57-5 HCAPLUS
CN Carbamic acid, N-[(1S,3S)-1-[(1S)-2-[[2-[(1,1-dimethylbutyl)methylamino]-3,4-dioxo-1-cyclobuten-1-yl]amino]-1-hydroxyethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester

(CA INDEX NAME)

Absolute stereochemistry.



RN 955021-64-4 HCAPLUS
CN Carbamic acid, N-[(1S,3S)-1-[(1S)-2-[(2-hexyl-3,4-dioxo-1-cyclobuten-1-yl)amino]-1-hydroxyethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-68-8 HCAPLUS
CN Carbamic acid, N-[(1S,3S)-1-[(1S)-1-hydroxy-2-[(4-methoxy-1,1-dioxido-1,2,5-thiadiazol-3-yl)amino]ethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 955021-69-9 HCAPLUS

CN Carbamic acid, N-[(1S,3S)-1-[(1S)-2-[[1,1-dioxido-4-[(2-phenylethyl)amino]-1,2,5-thiadiazol-3-yl]amino]-1-hydroxyethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:81037 HCAPLUS
DOCUMENT NUMBER: 146:162906
TITLE: phenylalkyldiaminoalcohols for treatment of Alzheimer's disease, malaria, or HIV infection.
INVENTOR(S): Herold, Peter; Stutz, Stefan; Tschinke, Vincenzo; Stojanovic, Aleksandar; Marti, Christiane; Quirmbach, Michael; Schumacher, Christoph
PATENT ASSIGNEE(S): Speedel Experimenta AG, Switz.
SOURCE: Eur. Pat. Appl., 22pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1745778	A2	20070124	EP 2006-117468	20060719
EP 1745778	A3	20070307		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
US 20070021413	A1	20070125	US 2006-488854	20060719

PRIORITY APPLN. INFO.: CH 2005-1209 A 20050720
OTHER SOURCE(S): MARPAT 146:162906
GI



I

AB Use of title compds. [I; R = 1-4 of H, halo, alkyl, cycloalkyl, polyhaloalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, hydroxyalkyl, alkylthioalkyl, imidazolylthioalkyl, etc.; R1 = H, OH, amino, (substituted) alkyl, cycloalkyl, alkanoyl, alkoxycarbonyl, aralkyl, heterocyclylalkyl; R2 = (substituted) alkyl, cycloalkyl, alkylsulfonyl, cycloalkylsulfonyl, aralkylsulfonyl, alkanoyl, alkoxycarbonyl, aralkyl, etc.; R1R2N = (substituted) (unsatd.) 4-8 membered heterocyclyl; R3, R4 = H, alkyl, alkoxycarbonyl, alkanoyl; R5 = H, alkyl; CR5R5 = C3-8 cycloalkylidene; R6 = H, OH], for the preparation of a medication for the inhibition of β-secretase, cathepsin D, plasmepsin II, and/or HIV protease, is claimed (no data).

IT 861899-84-5 861899-85-6 861899-87-8
861899-88-9 861899-90-3 861899-91-4
861899-92-5 861899-93-6 861899-94-7
861899-95-8 861899-96-9 861899-97-0
861899-98-1 861899-99-2 861900-01-8
861900-02-9 861900-03-0 861900-05-2
861900-06-3 861900-08-5 861900-09-6
861900-10-9 861900-11-0 861900-12-1
861900-15-4 861900-17-6 861900-19-8
861900-20-1 861900-22-3 861900-23-4
861900-25-6 861900-26-7 861900-28-9
861900-29-0 861900-30-3 861900-31-4
861900-32-5 861900-33-6 861900-34-7
861900-35-8 861900-36-9 861900-37-0
861900-38-1 861900-39-2 861900-40-5
861900-41-6 861900-42-7 861900-43-8
861900-44-9 861900-45-0 861900-46-1
861900-47-2 861900-48-3 861900-49-4
861900-50-7 861900-51-8 861900-52-9
861900-53-0 861900-54-1 861900-55-2
861900-56-3 861900-57-4 861900-58-5
861900-59-6 861900-60-9 861900-61-0
861900-62-1 861900-63-2 861900-64-3
861900-65-4 861900-66-5 861900-67-6
861900-68-7 861900-72-3 861900-73-4
861900-74-5 861900-75-6 861900-76-7
861900-77-8 861900-78-9 861900-79-0
861900-80-3 861900-81-4 861900-82-5
861900-83-6 861900-85-8 861900-86-9
861900-87-0 861900-88-1 861900-89-2
861900-90-5 861900-92-7 861900-93-8
861900-96-1 861900-97-2 861900-98-3
861900-99-4 861901-00-0 861901-03-3
861901-05-5 1033573-82-8 1033574-05-8
1033697-59-4 1033698-58-6 1033700-50-3
1033834-11-5 1033837-19-2 1033847-08-3

1033873-57-2 1033877-74-5 1033881-46-7
1057086-72-2 1057086-73-3 1057086-74-4
1057086-75-5 1057086-76-6 1057086-77-7
1057086-78-8 1057086-79-9 1057086-80-2
1057086-81-3 1057086-82-4 1057086-83-5
1057086-84-6 1057086-86-8 1057086-87-9
1069117-70-9
RL: PRPH (Prophetic)
(phenylalkyldiaminoalcohols for treatment of Alzheimer's disease, malaria, or HIV infection.)

RN 861899-84-5 HCAPLUS
CN Benzenepentanol, β-amino-α-[(dimethylamino)methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861899-85-6 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[(2-methylpropyl)amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861899-87-8 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[(phenylmethyl)amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861899-88-9 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[methyl(phenylmethyl)amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861899-90-3 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[(1-methylethyl)amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861899-91-4 HCAPLUS
CN Benzenepentanol, β-amino-α-[(cyclopropylamino)methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861899-92-5 HCAPLUS
CN Benzenepentanol, β-amino-α-[(ethylamino)methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861899-93-6 HCAPLUS
CN Benzenepentanol, β-amino-α-[(diethylamino)methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861899-94-7 HCAPLUS
CN Benzenepentanol, β-amino-α-[[(1,1-dimethylethyl)amino]methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861899-95-8 HCAPLUS
CN Benzenepentanol, β-amino-α-[(cyclopentylamino)methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861899-96-9 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[(propylamino)methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861899-97-0 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[methyl(1-methylethyl)amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861899-98-1 HCAPLUS
CN Benzenepentanol, β-amino-α-[[(1-ethylpropyl)amino]methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861899-99-2 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[(1-methylethyl)(phenylmethyl)amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861900-01-8 HCAPLUS
CN Acetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-02-9 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-α-[[(2-methoxyethyl)(1-

methylethyl)amino]methyl]-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861900-03-0 HCAPLUS
CN Acetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-05-2 HCAPLUS
CN Acetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-06-3 HCAPLUS
CN Formamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-08-5 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[[(1S)-1-methylpropyl]amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861900-09-6 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[[(1R)-1-methylpropyl]amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861900-10-9 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[[(1R)-1-methylpentyl]amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861900-11-0 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[[(1S)-1-methylpentyl]amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861900-12-1 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[[(1S)-1-methylhexyl]amino]methyl]-, hydrochloride

(1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861900-15-4 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[[(1R)-1-methylhexyl]amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861900-17-6 HCAPLUS
CN Methanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-19-8 HCAPLUS
CN Benzamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-20-1 HCAPLUS
CN Benzamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methoxy-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-22-3 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[(2-thiazolylamino)methyl]-, hydrochloride (1:1), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-23-4 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-25-6 HCAPLUS
CN Acetamide, 2-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861900-26-7 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-28-9 HCAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-

methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-29-0 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N,2,2-trimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-30-3 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-ethyl-2,2-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-31-4 HCAPLUS
CN Butanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-ethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-32-5 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-chloro-2,2-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-33-6 HCAPLUS
CN Acetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methoxy-, hydrochloride

(1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-34-7 HCAPLUS
CN Urea, N'-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-35-8 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-hydroxy-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 861900-36-9 HCAPLUS
CN Methanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-37-0 HCAPLUS
CN Cyclopropanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-38-1 HCAPLUS
CN Cyclohexanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-39-2 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-40-5 HCAPLUS
CN Urea, N'-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N,N-diethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-41-6 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methoxy-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-42-7 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methoxy-, hydrochloride (1:1), (2R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-43-8 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methoxy-, hydrochloride (1:1), (2S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-44-9 HCAPLUS
CN Benzenepentanol, β-amino-α-[[(1,1-dimethylpropyl)amino]methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861900-45-0 HCAPLUS
CN Benzenepentanol, β-amino-α-[[(1-ethyl-1-methylpropyl)amino]methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861900-46-1 HCAPLUS
CN Butanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-

methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-47-2 HCAPLUS
CN Pentanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-48-3 HCAPLUS
CN Hexanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-49-4 HCAPLUS
CN Cyclobutanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-50-7 HCAPLUS
CN Benzenesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-51-8 HCAPLUS
CN Propanamide, 2-(acetylamino)-N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-52-9 HCAPLUS
CN 2-Thiophenesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-53-0 HCAPLUS
CN Benzenemethanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-54-1 HCAPLUS
CN 1-Propanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-55-2 HCAPLUS
CN 1-Butanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-56-3 HCAPLUS
CN 2-Propanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-57-4 HCAPLUS
CN Cyclopropanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-58-5 HCAPLUS
CN Ethanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-59-6 HCAPLUS
CN Butanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-ethyl-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-60-9 HCAPLUS
CN Butanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-diethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-61-0 HCAPLUS
CN Cyclohexaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-62-1 HCAPLUS
CN Cyclopentaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-63-2 HCAPLUS
CN Cyclopropanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-phenyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-64-3 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-hydroxy-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 861900-65-4 HCAPLUS
CN Cyclobutanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-phenyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-66-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-phenyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-67-6 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-fluoro-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-68-7 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-hydroxy-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-72-3 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-chloro-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-73-4 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-chloro-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-74-5 HCAPLUS
CN Cyclobutanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-cyclohexyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-75-6 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-methoxy-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-76-7 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-methoxy-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-77-8 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α,4-trimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-78-9 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α,3-trimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-79-0 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-fluoro-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-80-3 HCAPLUS
CN 1-Piperidineacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861900-81-4 HCAPLUS
CN 4-Morpholineacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861900-82-5 HCAPLUS
CN Cyclobutanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-(4-chlorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-83-6 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-(cyclohexyloxy)-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-85-8 HCAPLUS
CN 1H-Indole-3-acetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-86-9 HCAPLUS
CN 3-Pyridineacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861900-87-0 HCAPLUS
CN 2H-Pyran-4-acetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]tetrahydro-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-88-1 HCAPLUS
CN 2-Pyridineacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861900-89-2 HCAPLUS
CN 4-Piperidineacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861900-90-5 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-methoxy-α-(trifluoromethyl)-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-92-7 HCAPLUS
CN Cyclohexaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-hydroxy-α,α-dimethyl-, hydrochloride (1:1), cis- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-93-8 HCAPLUS
CN Cyclohexaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-hydroxy-α,α-dimethyl-, hydrochloride (1:1), trans- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-96-1 HCAPLUS
CN Cyclohexaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-methoxy-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-97-2 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-methoxy-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-98-3 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-methoxy-α-methyl-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-99-4 HCAPLUS
CN Benzenepropanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-methoxy-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861901-00-0 HCAPLUS
CN Butanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methoxy-, hydrochloride

(1:1), (2R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861901-03-3 HCAPLUS
CN Cyclohexanepropanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-methoxy-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861901-05-5 HCAPLUS
CN Benzenepropanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-methoxy-α-methyl-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033573-82-8 HCAPLUS
CN Butanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methoxy-3,3-dimethyl-, hydrochloride (1:1), (2R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033574-05-8 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,3,3-trifluoro-2-methoxy-2-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033697-59-4 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,3,3-trifluoro-2-methoxy-2-

methyl-, hydrochloride (1:1), (2R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033698-58-6 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,3,3-trifluoro-2-methoxy-2-methyl-, hydrochloride (1:1), (2S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033700-50-3 HCAPLUS
CN Cyclohexaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-methoxy-α-methyl-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033834-11-5 HCAPLUS
CN 1H-Imidazole-1-acetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 1033837-19-2 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-cyano-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033847-08-3 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-difluoro-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033873-57-2 HCAPLUS
CN 2-Propanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033877-74-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-methoxy-, hydrochloride

(1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033881-46-7 HCAPLUS
CN Cyclohexanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-methoxy-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1057086-72-2 HCAPLUS
CN 2-Piperidineacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:2), (2R)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 1057086-73-3 HCAPLUS
CN 2-Piperidineacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:2), (2S)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 1057086-74-4 HCAPLUS
CN Cyclohexaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-hydroxy-α,α-dimethyl-, hydrochloride (1:1), (1S,2R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1057086-75-5 HCAPLUS
CN Cyclohexanepropanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-hydroxy-α-methyl-, hydrochloride (1:1), (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1057086-76-6 HCAPLUS
CN 3-Piperidineacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α,1-trimethyl-, hydrochloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1057086-77-7 HCAPLUS
CN 2-Piperidineacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α,1-trimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1057086-78-8 HCAPLUS
CN Cyclohexaneacetamide, 3-(acetylamino)-N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1057086-79-9 HCAPLUS
CN Cyclohexaneacetamide, 4-(acetylamino)-N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:1), trans- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1057086-80-2 HCAPLUS
CN Cyclohexaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-difluoro-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1057086-81-3 HCAPLUS
CN 2H-Pyran-4-acetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-difluorotetrahydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 1057086-82-4 HCAPLUS
CN Cyclohexanemethanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1057086-83-5 HCAPLUS
CN 3-Piperidineacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α,1-trimethyl-, hydrochloride (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1057086-84-6 HCAPLUS
CN Cyclohexaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-hydroxy-α,α-dimethyl-, hydrochloride (1:1), (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1057086-86-8 HCAPLUS
CN Benzenepentanol, β-amino-α-[(cyclopropylmethylamino)methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 1057086-87-9 HCAPLUS
CN Propanamide, 2-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-, hydrochloride (1:2), (2S)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 1069117-70-9 HCAPLUS
CN Benzeneacetamide, N-[3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-fluoro-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:796048 HCAPLUS
DOCUMENT NUMBER: 145:230398
TITLE: 1-Acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors and their preparation, pharmaceutical compositions and their use for treatment of hypertension
INVENTOR(S): Mcgeehan, Gerard; Simpson, Robert D.; Zeng, Wenguang; Baldwin, John J.; Claremon, David A.; Dillard, Lawrence W.; Ishchenko, Alexey V.; Yuan, Jing; Xu, Zhenrong; Cacatian, Slavation; Tice, Colin; Zhao, Wei
PATENT ASSIGNEE(S): Vitae Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 149pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2006083924 A1 20060810 WO 2006-US3489 20060201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
CA 2596444 A1 20060810 CA 2006-2596444 20060201
EP 1844002 A1 20071017 EP 2006-720036 20060201
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
JP 2008528691 T 20080731 JP 2007-554177 20060201
US 20080293701 A1 20081127 US 2008-883518 20080707
PRIORITY APPLN. INFO.: US 2005-649361P P 20050202
WO 2006-US3489 W 20060201
OTHER SOURCE(S): CASREACT 145:230398; MARPAT 145:230398
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB 1-Acylamino-2-hydroxy-3-amino-ω-arylalkanes of formula I and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive, medicinally active ingredients. Compds. of formula I wherein R1 is H, Oh, halo, lower alkoxy, cycloalkoxy, etc.; R2 and R2 are independently H, halo, CN, carbamoyl, lower (halo)alkyl, etc.; R4 is H, lower alkyl, OH, lower alkoxy, cycloalkoxy, etc.; R2 and R3 or R3 and R4 taken together with the atoms they are attached form a fused (un)substituted dioxolane, (un)substituted dioxane, (un)substituted benzene or (un)substituted cyclohexene; R5 is lower (halo)alkyl, (halo)cycloalkyl, lower (halo)alkyl-cycloalkyl, aryl, heterocyclyl, etc.; R6 is amino, lower (di)alkylamino, or lower alkanoylamino; R7 is H, lower (halo)alkylcycloalkyl, or lower (halo)alkoxy-lower alkyl; X is methylene or hydroxymethylene; Q is Co, CS, or SO2; R8 is lower (halo)alkyl, C8-15 (halo)alkyl, (halo)cycloalkyl, lower alkyl-cycloalkyl, etc.; and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof are claimed. Example compound II•HCl was prepared by aminolysis of compound III to give the corresponding diamino alc., which underwent amidation with cyclohexanecarboxylic acid to give tert-Bu (2S,3S,5S)-5-(3-(3-methoxypropoxy)-4-methoxybenzyl)-1-(cyclohexanecarbonyl)amino-2-hydroxy-6-methylheptan-3-ylcarbamate, which underwent acid hydrolysis to give compound II•HCl. All the invention compds. were evaluated for their renin inhibitory activity (no data).

IT 1044721-80-3 1044721-81-4 1044721-82-5
1044721-83-6 1044721-84-7 1044721-85-8
1044721-87-0 1044721-88-1 1044721-89-2
1044721-90-5 1044721-91-6 1044721-93-8
1044721-94-9 1044721-95-0 1044721-96-1
1044721-97-2 1044721-99-4 1044722-00-0

1044722-03-3 1044722-05-5 1044722-06-6
1044722-08-8 1044722-11-3 1044722-13-5
1044722-14-6 1044722-16-8 1044722-19-1
1044722-20-4 1044722-21-5 1044722-24-8
1044722-25-9 1044722-28-2 1044722-29-3
1044722-30-6 1044722-33-9 1044722-35-1
1044722-36-2 1044722-38-4 1044722-40-8
1044722-43-1 1044722-45-3 1044722-46-4
1044722-48-6 1044722-50-0 1044722-53-3
1044722-54-4 1044722-56-6 1044722-58-8
1044722-61-3 1044722-62-4 1044722-64-6
1044722-66-8 1044722-69-1 1044722-70-4
1044722-72-6 1044722-73-7 1044722-75-9
1044722-76-0 1044722-77-1 1044722-78-2
1044722-79-3 1044722-80-6 1044722-81-7
1044722-82-8 1044722-83-9 1044722-84-0
1044722-85-1 1044722-86-2 1044722-87-3
1044722-88-4 1044722-89-5 1044722-91-9
1044722-92-0 1044722-93-1 1044722-94-2
1044722-95-3 1044722-96-4 1044722-97-5
1044722-98-6 1044722-99-7 1044723-00-3
1044723-01-4 1044723-02-5 1044723-03-6
1044723-04-7 1044723-05-8 1044723-06-9
1044723-07-0 1044723-08-1 1044723-09-2
1044723-10-5 1044723-11-6 1044723-12-7
1044723-13-8 1044723-14-9 1044723-15-0
1044723-16-1 1044723-17-2 1044723-18-3
1044723-19-4 1044723-20-7
RL: PRPH (Prophetic)
(1-Acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors and their preparation, pharmaceutical compns. and their use for treatment of hypertension)

RN 1044721-80-3 HCAPLUS
CN Benzamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044721-81-4 HCAPLUS
CN Urea, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(2-cyclopropylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044721-82-5 HCAPLUS
CN Benzeneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-fluoro-α,α-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044721-83-6 HCAPLUS
CN Benzeneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044721-84-7 HCAPLUS
CN Benzenepropanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-β-hydroxy-α,α-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044721-85-8 HCAPLUS
CN Urea, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-methyl-N'-pentyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044721-87-0 HCAPLUS
CN Cyclopentanecarboxamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044721-88-1 HCAPLUS
CN Cyclohexanecarboxamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044721-89-2 HCAPLUS
CN Urea, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(cyclohexylmethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044721-90-5 HCAPLUS
CN Benzeneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-(trifluoromethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044721-91-6 HCAPLUS
CN Propanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methyl-2-propoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044721-93-8 HCAPLUS
CN Propanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-(4-cyanophenoxy)-2-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044721-94-9 HCAPLUS
CN Benzenepropanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044721-95-0 HCAPLUS
CN Urea, N'-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-cyclohexyl-N-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044721-96-1 HCAPLUS
CN Cyclopropanecarboxamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-(2,4-dichlorophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044721-97-2 HCAPLUS
CN Pentanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-5,5,5-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044721-99-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 1044722-00-0 HCAPLUS
CN Benzeneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-fluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-03-3 HCAPLUS
CN Sulfamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-butyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-05-5 HCAPLUS
CN Hexanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-06-6 HCAPLUS
CN Benzeneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-cyano-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-08-8 HCAPLUS
CN 1-Butanesulfonamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-11-3 HCAPLUS
CN Benzenebutanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-13-5 HCAPLUS
CN Butanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-14-6 HCAPLUS
CN Benzeneacetamide, N-[(2R,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-16-8 HCAPLUS
CN Butanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-19-1 HCAPLUS
CN Urea, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(1,1-dimethylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-20-4 HCAPLUS
CN Cyclopropanecarboxamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-(4-methylphenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-21-5 HCAPLUS
CN Hexanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-24-8 HCAPLUS
CN Urea, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(2-ethoxyethyl)-, rel-

(CA INDEX NAME)

Relative stereochemistry.



RN 1044722-25-9 HCAPLUS
CN Cyclopropanecarboxamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-(4-methoxyphenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-28-2 HCAPLUS
CN Urea, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-hexyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-29-3 HCAPLUS
CN Cyclopropanecarboxamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-(4-chlorophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-30-6 HCAPLUS
CN Hexanamide, N-[(2R,3R,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-33-9 HCAPLUS
CN Urea, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(1,1-dimethylpentyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-35-1 HCAPLUS
CN Hexanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-ethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-36-2 HCAPLUS
CN Urea, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(2-cyclohexylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-38-4 HCAPLUS
CN Propanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-(4-chlorophenoxy)-2-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-40-8 HCAPLUS
CN Urea, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(3-phenylpropyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-43-1 HCAPLUS
CN Cyclohexanecarboxamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-(4-fluorophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-45-3 HCAPLUS
CN Urea, N'-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N,N-bis(2-methylpropyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-46-4 HCAPLUS
CN Benzeneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,3-difluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-48-6 HCAPLUS
CN 1-Butanesulfonamide, N-[(2R,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-50-0 HCAPLUS
CN Cyclohexaneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-53-3 HCAPLUS
CN Benzenemethanesulfonamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-54-4 HCAPLUS
CN Benzeneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,4-difluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-56-6 HCAPLUS
CN Heptanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-58-8 HCAPLUS
CN Urea, N-[(2R,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-pentyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-61-3 HCAPLUS
CN Urea, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-pentyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-62-4 HCAPLUS
CN Propanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,3,3-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-64-6 HCAPLUS
CN Benzeneacetamide, N-[(2R,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-fluoro-α,α-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-66-8 HCAPLUS
CN Butanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4,4,4-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-69-1 HCAPLUS
CN Cyclopentaneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-butyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-70-4 HCAPLUS
CN Urea, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-[2-(4-fluorophenyl)-1,1-dimethylethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-72-6 HCAPLUS
CN Urea, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(3-fluorophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-73-7 HCAPLUS
CN Benzeneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-(trifluoromethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-75-9 HCAPLUS
CN Sulfamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-butyl-N-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-76-0 HCAPLUS
CN Cyclohexanecarboxamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-77-1 HCAPLUS
CN Propanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-ethoxy-2,2-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-78-2 HCAPLUS
CN Propanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,3,3-trifluoro-2-methyl-2-(trifluoromethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-79-3 HCAPLUS
CN Benzeneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-80-6 HCAPLUS
CN Hexanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N,2,2-trimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-81-7 HCAPLUS
CN Benzeneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-fluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-82-8 HCAPLUS
CN Cyclopropanebutanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-83-9 HCAPLUS
CN Urea, N'-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-methyl-N-pentyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-84-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 1044722-85-1 HCAPLUS
CN Hexanamide, N-[(2R,3R,5R)-3-amino-5-[[3-(2-cyclopropylethoxy)phenyl]methyl]-2-hydroxy-6-methylheptyl]-2,2-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-86-2 HCAPLUS
CN 1-Pentanesulfonamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-87-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 1044722-88-4 HCAPLUS
CN Sulfamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-

methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-(1-methylethyl)-N'-2-propen-1-yl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-89-5 HCAPLUS
CN Pentanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-91-9 HCAPLUS
CN Hexanamide, N-[(2R,3R,5R)-3-amino-5-[[4-bromo-3-(3-methoxypropoxy)phenyl]methyl]-2-hydroxy-6-methylheptyl]-2,2-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-92-0 HCAPLUS
CN 1-Butanesulfonamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-93-1 HCAPLUS
CN Cyclopropanecarboxamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-94-2 HCAPLUS
CN Butanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-95-3 HCAPLUS
CN Hexanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-96-4 HCAPLUS
CN Benzenesulfonamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-97-5 HCAPLUS
CN Benzeneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-98-6 HCAPLUS
CN Benzeneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,4-difluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044722-99-7 HCAPLUS
CN Butanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,3-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-00-3 HCAPLUS
CN Urea, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-butyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-01-4 HCAPLUS
CN Pentanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-02-5 HCAPLUS
CN Urea, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(3-methoxypropyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-03-6 HCAPLUS
CN Cyclopentaneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-04-7 HCAPLUS
CN Urea, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-cyclohexyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-05-8 HCAPLUS
CN Cyclohexaneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-06-9 HCAPLUS
CN Urea, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(2,2-dimethylpentyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-07-0 HCAPLUS
CN Benzeneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-(trifluoromethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-08-1 HCAPLUS
CN Hexanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,3-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-09-2 HCAPLUS
CN Urea, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(2-phenylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-10-5 HCAPLUS
CN Urea, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(1,1,3,3-tetramethylbutyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-11-6 HCAPLUS
CN Benzeneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-(trifluoromethoxy)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-12-7 HCAPLUS
CN Urea, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-[3-(trifluoromethyl)phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-13-8 HCAPLUS
CN Benzeneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-diethyl-4-fluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-14-9 HCAPLUS
CN Benzeneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-fluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-15-0 HCAPLUS
CN 4-Morpholinecarboxamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-16-1 HCAPLUS
CN Pentanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-17-2 HCAPLUS
CN Cyclopropanebutanamide, N-[(2R,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-18-3 HCAPLUS
CN Cyclopropaneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-19-4 HCAPLUS
CN Benzenesulfonamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044723-20-7 HCAPLUS
CN Propanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 861922-75-0P 861922-79-4P 861922-93-2P
861922-94-3P 861923-01-5P 861923-02-6P
861923-03-7P 861923-05-9P 861923-10-6P
861923-16-2P 861923-18-4P 861923-20-8P
861923-33-3P 905829-77-8P 905829-78-9P
905829-79-0P 905829-81-4P 905829-82-5P
905829-84-7P 905829-86-9P 905829-88-1P
905829-91-6P 905829-95-0P 905829-99-4P
905830-02-6P 905830-03-7P 905830-04-8P
905830-05-9P 905830-06-0P 905830-07-1P
905830-08-2P 905830-09-3P 905830-10-6P
905830-11-7P 905830-12-8P 905830-13-9P
905830-14-0P 905830-15-1P 905830-16-2P
905830-17-3P 905830-18-4P 905830-19-5P
905830-20-8P 905830-21-9P 905830-22-0P
905830-23-1P 905830-24-2P 905830-25-3P
905830-26-4P 905830-27-5P 905830-28-6P
905830-29-7P 905830-30-0P 905830-31-1P
905830-32-2P 905830-33-3P 905830-34-4P
905830-35-5P 905830-36-6P 905830-37-7P
905830-38-8P 905830-39-9P 905830-40-2P
905830-41-3P 905830-42-4P 905830-43-5P
905830-44-6P 905830-45-7P 905830-46-8P
905830-47-9P 905830-48-0P 905830-49-1P
905830-50-4P 905830-51-5P 905830-52-6P
905830-53-7P 905830-54-8P 905830-55-9P
905830-56-0P 905830-57-1P 905830-58-2P
905830-59-3P 905830-60-6P 905830-61-7P
905830-62-8P 905830-63-9P 905830-64-0P
905830-65-1P 905830-66-2P 905830-67-3P
905830-68-4P 905830-69-5P 905830-70-8P

905830-71-9P 905830-72-0P 905830-73-1P
905830-74-2P 905830-75-3P 905830-76-4P
905830-77-5P 905830-78-6P 905830-79-7P
905830-80-0P 905830-81-1P 905830-82-2P
905830-83-3P 905830-84-4P 905830-85-5P
905830-86-6P 905830-87-7P 905830-88-8P
905830-89-9P 905831-21-2P 905831-22-3P
905840-94-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of acylamino(hydroxy)amino-ω-arylalkanes as renin-inhibitors useful as antihypertensive)

RN 861922-75-0 HCAPLUS
CN Benzamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 861922-79-4 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 861922-93-2 HCAPLUS
CN Cyclohexanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 861922-94-3 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 861923-01-5 HCAPLUS
CN Butanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 861923-02-6 HCAPLUS
CN Pentanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 861923-03-7 HCAPLUS
CN Hexanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 861923-05-9 HCAPLUS
CN Benzenesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 861923-10-6 HCAPLUS
CN 1-Butanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 861923-16-2 HCAPLUS

CN Cyclohexaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 861923-18-4 HCAPLUS
CN Cyclopropanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 861923-20-8 HCAPLUS
CN Cyclopentanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 861923-33-3 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-fluoro-α,α-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905829-77-8 HCAPLUS
CN Cyclohexanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



RN 905829-78-9 HCAPLUS
CN Hexanamide, N-[(2S,3S,5S)-3-amino-5-[[4-ethyl-3-(3-methoxypropoxy)phenyl]methyl]-2-hydroxy-6-methylheptyl]-2,2-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 905829-79-0 HCAPLUS
CN Hexanamide, N-[(2R,3S,5S)-3-amino-5-[[4-ethyl-3-(3-methoxypropoxy)phenyl]methyl]-2-hydroxy-6-methylheptyl]-2,2-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 905829-81-4 HCAPLUS
CN Hexanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[2-(3-methoxypropoxy)[1,1'-biphenyl]-4-yl]methyl]-6-methylheptyl]-2,2-dimethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 905829-80-3
CMF C33 H52 N2 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 905829-82-5 HCAPLUS
CN Benzenemethanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 861923-08-2
CMF C27 H42 N2 O6 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 905829-84-7 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(phenylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 905829-86-9 HCAPLUS
CN 1-Piperidinecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 905829-88-1 HCAPLUS
CN Propanamide, 3-[[[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]carbonyl]amino]-2,2-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 905829-91-6 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 905829-90-5
CMF C21 H37 N3 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 905829-95-0 HCAPLUS
CN Thiourea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-pentyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 905829-94-9
CMF C26 H47 N3 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 905829-99-4 HCAPLUS
CN Carbamic acid, [(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, pentyl ester, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 905829-98-3
CMF C26 H46 N2 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 905830-02-6 HCAPLUS
CN Sulfamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-pentyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 905830-01-5

CMF C25 H47 N3 O6 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 905830-03-7 HCAPLUS
CN Butanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-04-8 HCAPLUS
CN Cyclopropaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-05-9 HCAPLUS
CN Pentanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-06-0 HCAPLUS
CN Hexanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-07-1 HCAPLUS
CN Butanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,3-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-08-2 HCAPLUS
CN Butanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-methoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-09-3 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,3,3-trifluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-10-6 HCAPLUS
CN Cyclopentaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-11-7 HCAPLUS
CN Heptanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-12-8 HCAPLUS
CN Hexanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-13-9 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-14-0 HCAPLUS
CN Butanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4,4,4-trifluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-15-1 HCAPLUS
CN Cyclohexaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-16-2 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-[2-(4-fluorophenyl)-1,1-dimethylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-17-3 HCAPLUS
CN Hexanamide, N-[(2R,3R,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-dimethyl- (CA INDEX

NAME)

Absolute stereochemistry.



RN 905830-18-4 HCAPLUS
CN Hexanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,3-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-19-5 HCAPLUS
CN Hexanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-20-8 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methyl-2-propoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-21-9 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-ethoxy-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-22-0 HCAPLUS
CN Benzenepropanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-23-1 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-24-2 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-25-3 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-26-4 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-27-5 HCAPLUS
CN Pentanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-5,5,5-trifluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-28-6 HCAPLUS
CN Cyclopropanebutanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-29-7 HCAPLUS
CN Cyclopropanebutanamide, N-[(2R,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-30-0 HCAPLUS
CN Hexanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,5,5-trimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-31-1 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-cyano- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-32-2 HCAPLUS
CN Benzenebutanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-33-3 HCAPLUS
CN Benzeneacetamide, N-[(2R,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-34-4 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,4-difluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-35-5 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,4-difluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-36-6 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,3-difluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-37-7 HCAPLUS
CN Cyclopropanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-(4-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-38-8 HCAPLUS
CN Benzeneacetamide, N-[(2R,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-fluoro-α,α-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-39-9 HCAPLUS
CN Cyclopentaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-butyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-40-2 HCAPLUS
CN Cyclopropanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-(4-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-41-3 HCAPLUS
CN Benzenepropanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-

methoxypropoxy)phenyl]methyl]-6-methylheptyl]-β-hydroxy-α,α-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-42-4 HCAPLUS
CN Cyclopropanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-(4-chlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-43-5 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-44-6 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-(trifluoromethyl)- (CA

INDEX NAME)

Absolute stereochemistry.



RN 905830-45-7 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-46-8 HCAPLUS
CN Cyclohexanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-47-9 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-(4-cyanophenoxy)-2-methyl-

(CA INDEX NAME)

Absolute stereochemistry.



RN 905830-48-0 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,3,3-trifluoro-2-methyl-2-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-49-1 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-diethyl-4-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-50-4 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-(4-chlorophenoxy)-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-51-5 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-(trifluoromethoxy)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-52-6 HCAPLUS
CN Cyclohexanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-(4-fluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-53-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-(2,4-dichlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-54-8 HCAPLUS
CN Hexanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N,2,2-trimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-55-9 HCAPLUS
CN Pentanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-56-0 HCAPLUS
CN Hexanamide, N-[(2S,3S,5S)-3-amino-5-[[3-(2-cyclopropylethoxy)phenyl]methyl]-2-hydroxy-6-methylheptyl]-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-57-1 HCAPLUS
CN Hexanamide, N-[(2S,3S,5S)-3-amino-5-[[3-(3-ethoxypropoxy)phenyl]methyl]-2-hydroxy-6-methylheptyl]-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-58-2 HCAPLUS
CN Hexanamide, N-[(2S,3S,5S)-3-amino-5-[[4-bromo-3-(3-methoxypropoxy)phenyl]methyl]-2-hydroxy-6-methylheptyl]-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-59-3 HCAPLUS
CN 1-Pentanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-60-6 HCAPLUS
CN 1-Butanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-61-7 HCAPLUS
CN 1-Butanesulfonamide, N-[(2R,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-62-8 HCAPLUS
CN Benzenesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-63-9 HCAPLUS
CN Benzenemethanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-(1-methylethyl)- (CA

INDEX NAME)

Absolute stereochemistry.



RN 905830-64-0 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-butyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-65-1 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(1,1-dimethylethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-66-2 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(2-cyclopropylethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-67-3 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-pentyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-68-4 HCAPLUS
CN Urea, N-[(2R,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-pentyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-69-5 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(3-methoxypropyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-70-8 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(2-ethoxyethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-71-9 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-cyclohexyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-72-0 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-hexyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-73-1 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-methyl-N'-pentyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-74-2 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(3-fluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-75-3 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(cyclohexylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-76-4 HCAPLUS
CN Sulfamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-butyl-N-(1-methylethyl)-(CA INDEX NAME)

Absolute stereochemistry.



RN 905830-77-5 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(2,2-dimethylpentyl)-(CA INDEX NAME)

Absolute stereochemistry.



RN 905830-78-6 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(1,1-dimethylpentyl)-(CA INDEX NAME)

Absolute stereochemistry.



RN 905830-79-7 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(2-phenylethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-80-0 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(2-cyclohexylethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-81-1 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(1,1,3,3-tetramethylbutyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-82-2 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-(3-phenylpropyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-83-3 HCAPLUS
CN Urea, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-84-4 HCAPLUS
CN 4-Morpholinecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-85-5 HCAPLUS
CN Urea, N'-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-methyl-N-pentyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-86-6 HCAPLUS
CN Urea, N'-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-cyclohexyl-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-87-7 HCAPLUS
CN Urea, N'-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N,N-bis(2-methylpropyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-88-8 HCAPLUS
CN Carbamic acid, [(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-89-9 HCAPLUS
CN Carbamic acid, [(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905831-21-2 HCAPLUS
CN Sulfamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N'-butyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905831-22-3 HCAPLUS
CN Sulfamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-(1-methylethyl)-N'-2-propen-1-yl- (CA INDEX NAME)

Absolute stereochemistry.



RN 905840-94-0 HCAPLUS
CN Cyclohexanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.



IT 861901-11-3P 905830-93-5P 905831-04-1P
905831-05-2P 905831-06-3P 905831-07-4P
905831-08-5P 905831-09-6P 905831-11-0P
905831-12-1P 905831-14-3P 905831-16-5P
905831-17-6P 905831-18-7P 905831-20-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of acylamino(hydroxy)amino-ω-arylalkanes as renin-inhibitors useful as antihypertensive)
RN 861901-11-3 HCAPLUS
CN Carbamic acid, N-[(1S,3S)-1-[(1S)-2-amino-1-hydroxyethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 905830-93-5 HCAPLUS
CN Carbamic acid, [(1S,3S)-1-[(1S)-2-[(cyclohexylcarbonyl)amino]-1-hydroxyethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905831-04-1 HCAPLUS
CN Carbamic acid, [(1S,3S)-1-[(1S)-2-amino-1-hydroxyethyl]-4-methyl-3-[[3-(phenylmethoxy)phenyl]methyl]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905831-05-2 HCAPLUS
CN Carbamic acid, [(1S,3S)-1-[(1S)-2-[(2,2-dimethyl-1-oxohexyl)amino]-1-hydroxyethyl]-4-methyl-3-[[3-(phenylmethoxy)phenyl]methyl]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905831-06-3 HCAPLUS
CN Carbamic acid, [(1S,3S)-1-[(1S)-2-[(2,2-dimethyl-1-oxohexyl)amino]-1-hydroxyethyl]-3-[(3-hydroxyphenyl)methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905831-07-4 HCAPLUS
CN Carbamic acid, [(1S,3S)-3-[(4-bromo-3-hydroxyphenyl)methyl]-1-[(1S)-2-[(2,2-dimethyl-1-oxohexyl)amino]-1-hydroxyethyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905831-08-5 HCAPLUS
CN Carbamic acid, [(1S,3S)-1-[(1S)-2-[(2,2-dimethyl-1-oxohexyl)amino]-1-hydroxyethyl]-3-[(2-hydroxy[1,1'-biphenyl]-4-yl)methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905831-09-6 HCAPLUS
CN Carbamic acid, [(1S,3S)-1-[(1S)-2-[(2,2-dimethyl-1-oxohexyl)amino]-1-hydroxyethyl]-3-[[2-(3-methoxypropoxy)[1,1'-biphenyl]-4-yl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905831-11-0 HCAPLUS
CN Carbamic acid, [(1S,3S)-1-[(1S)-1-hydroxy-2-[[[(phenylmethyl)amino]carbonyl]amino]ethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905831-12-1 HCAPLUS
CN Carbamic acid, [(1S,3S)-1-[(1S)-1-hydroxy-2-[(1-piperidinylcarbonyl)amino]ethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905831-14-3 HCAPLUS
CN Carbamic acid, [(1S,3S)-1-[(1S)-2-[[[(3-amino-2,2-dimethyl-3-oxopropyl)amino]carbonyl]amino]-1-hydroxyethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905831-16-5 HCAPLUS
CN Carbamic acid, [(1S,3S)-1-[(1S)-1-hydroxy-2-[[[(1-methyl-1-phenylethyl)amino]carbonyl]amino]ethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905831-17-6 HCAPLUS
CN Carbamic acid, [(1S,3S)-1-[(1S)-1-hydroxy-2-[[(pentylamino)thioxomethyl]amino]ethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905831-18-7 HCAPLUS
CN Carbamic acid, [(2S,3S,5S)-3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, pentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 905831-20-1 HCAPLUS
CN 3-Thia-2,4,8-triazanonanedioic acid, 6-hydroxy-7-[(2S)-2-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-3-methylbutyl]-2-pentyl-, 1,9-bis(1,1-dimethylethyl) ester, 3,3-dioxide, (6S,7S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 955020-79-8 1057394-39-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of acylamino(hydroxy)amino-ω-arylalkanes as renin-inhibitors useful as antihypertensive)

RN 955020-79-8 HCAPLUS
CN Carbamic acid, N-[(1S,3S)-1-[(1S)-1-hydroxy-2-(methylamino)ethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1057394-39-4 HCAPLUS
CN Carbamic acid, N-[(1R,3S)-1-[(1R)-2-amino-1-hydroxyethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:696868 HCAPLUS
DOCUMENT NUMBER: 143:193798
TITLE: Preparation of diamino alcohols as renin inhibitors
INVENTOR(S): Herold, Peter; Stutz, Stefan; Stojanovic, Aleksandar; Tschinke, Vincenzo; Marti, Christiane; Quirmbach, Michael
PATENT ASSIGNEE(S): Speedel Experimenta A.-G., Switz.
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070877	A1	20050804	WO 2005-EP50272	20050121

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2553831	A1	20050804	CA 2005-2553831		20050121
EP 1735270	A1	20061227	EP 2005-701590		20050121
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR					
CN 1910141	A	20070207	CN 2005-80002920		20050121
BR 2005007067	A	20070612	BR 2005-7067		20050121
JP 2007522123	T	20070809	JP 2006-550176		20050121
IN 2006DN04188	A	20070713	IN 2006-DN4188		20060720
US 20070161622	A1	20070712	US 2006-586814		20060724
PRIORITY APPLN. INFO.:			CH 2004-94	A	20040123
			WO 2005-EP50272	W	20050121

OTHER SOURCE(S): CASREACT 143:193798; MARPAT 143:193798

GI



I



II

AB Title compds. I [R1 = H, OH, NH2, etc.; R2 = (un)substituted alkyl, cycloalkyl, alkylsuphonyl, etc. or R1 and R2 together can form with the nitrogen atom that they are attached to a (un)saturated, (un)substituted 4-8 membered heterocycle containing an addnl. N, O or S, etc.; R3 = H, alkoxycarbonyl, alkanoyl, etc.; R4 = H, alkyl, alkoxycarbonyl, etc.; R5 independently = H, alkyl or together cycloalkylidene; R6 = H or OH; R = H,

halo, alkoxyalkyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as renin inhibitors. Thus, e.g., II was prepared by coupling of tert-butyl{3(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-4-methyl-1(S)-(R)-oxiranylpentyl}-carbamate (preparation given) with piperidine and subsequent deprotection. The activity of I was evaluated in vitro monitoring the reduction of the formation of angiotensin I in different systems (no data). I as renin inhibitor should prove useful in the treatment of hypertension, heart failure and glaucoma. Pharmaceutical compns. comprising I are disclosed.

IT 1044676-39-2 1044676-40-5 1044676-41-6
1044676-42-7 1044676-43-8 1044676-44-9
1044676-45-0 1044676-46-1 1044676-47-2
1044676-48-3 1044676-49-4 1044676-50-7
1044676-51-8 1044676-52-9 1044676-53-0
1044676-54-1 1044676-57-4 1044676-58-5
1044676-60-9 1044676-61-0 1044676-62-1
RL: PRPH (Prophetic)
(Preparation of diamino alcohols as renin inhibitors)

RN 1044676-39-2 HCAPLUS

CN Cyclohexaneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-methoxy-α-methyl-, hydrochloride (1:1), (αR)-rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 1044676-40-5 HCAPLUS

CN Propanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-cyano-2-methyl-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 1044676-41-6 HCAPLUS
CN Cyclohexaneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-hydroxy-α,α-dimethyl-, hydrochloride (1:1), trans-rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 1044676-42-7 HCAPLUS
CN 2H-Pyran-4-acetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-difluorotetrahydro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044676-43-8 HCAPLUS

CN Propanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,3,3-trifluoro-2-methoxy-2-methyl-, hydrochloride (1:1), (2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 1044676-44-9 HCAPLUS
CN Cyclohexaneacetamide, 4-(acetylamino)-N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:1), trans-rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 1044676-45-0 HCAPLUS
CN 1H-Imidazole-1-acetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:2), rel- (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 1044676-46-1 HCAPLUS
CN Benzeneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-difluoro-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 1044676-47-2 HCAPLUS
CN Cyclohexanemethanesulfonamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 1044676-48-3 HCAPLUS
CN Propanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,3,3-trifluoro-2-methoxy-2-(trifluoromethyl)-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 1044676-49-4 HCAPLUS
CN Propanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,3,3-trifluoro-2-methoxy-2-methyl-, hydrochloride (1:1), (2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 1044676-50-7 HCAPLUS
CN Cyclohexanecarboxamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-methoxy-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 1044676-51-8 HCAPLUS
CN Cyclohexanepropanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-hydroxy-α-methyl-, hydrochloride (1:1), (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 1044676-52-9 HCAPLUS
CN Cyclohexaneacetamide, 3-(acetylamino)-N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:1), (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 1044676-53-0 HCAPLUS
CN 2-Propanesulfonamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methyl-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 1044676-54-1 HCAPLUS
CN Butanamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methoxy-3,3-dimethyl-, hydrochloride (1:1), (2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 1044676-57-4 HCAPLUS
CN Cyclopentanecarboxamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-methoxy-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 1044676-58-5 HCAPLUS
CN 2-Piperidineacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α,1-trimethyl-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 1044676-60-9 HCAPLUS
CN Cyclohexaneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-difluoro-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 1044676-61-0 HCAPLUS
CN Cyclohexaneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-hydroxy-α,α-dimethyl-, hydrochloride (1:1), cis-rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 1044676-62-1 HCAPLUS
CN Cyclohexaneacetamide, N-[(2R,3R,5R)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-methoxy-α-(trifluoromethyl)-, hydrochloride (1:1), (αR)-rel- (CA INDEX NAME)

Relative stereochemistry.



● HCl

IT 861899-84-5P 861899-85-6P 861899-87-8P
861899-88-9P 861899-90-3P 861899-91-4P
861899-92-5P 861899-93-6P 861899-94-7P
861899-95-8P 861899-96-9P 861899-97-0P
861899-98-1P 861899-99-2P 861900-00-7P
861900-01-8P 861900-02-9P 861900-03-0P
861900-05-2P 861900-06-3P 861900-08-5P
861900-09-6P 861900-10-9P 861900-11-0P
861900-12-1P 861900-15-4P 861900-17-6P
861900-19-8P 861900-20-1P 861900-22-3P
861900-23-4P 861900-24-5P 861900-25-6P
861900-26-7P 861900-28-9P 861900-29-0P
861900-30-3P 861900-31-4P 861900-32-5P
861900-33-6P 861900-34-7P 861900-35-8P
861900-36-9P 861900-37-0P 861900-38-1P
861900-39-2P 861900-40-5P 861900-41-6P
861900-42-7P 861900-43-8P 861900-44-9P
861900-45-0P 861900-46-1P 861900-47-2P
861900-48-3P 861900-49-4P 861900-50-7P
861900-51-8P 861900-52-9P 861900-53-0P
861900-54-1P 861900-55-2P 861900-56-3P
861900-57-4P 861900-58-5P 861900-59-6P
861900-60-9P 861900-61-0P 861900-62-1P
861900-63-2P 861900-64-3P 861900-65-4P
861900-66-5P 861900-67-6P 861900-68-7P
861900-72-3P 861900-73-4P 861900-74-5P
861900-75-6P 861900-76-7P 861900-77-8P
861900-78-9P 861900-79-0P 861900-80-3P
861900-81-4P 861900-82-5P 861900-83-6P
861900-84-7P 861900-85-8P 861900-86-9P
861900-87-0P 861900-88-1P 861900-89-2P
861900-90-5P 861900-91-6P 861900-92-7P
861900-93-8P 861900-94-9P 861900-95-0P
861900-96-1P 861900-97-2P 861900-98-3P
861900-99-4P 861901-00-0P 861901-02-2P
861901-03-3P 861901-04-4P 861901-05-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diamino alcs. as renin inhibitors)

RN 861899-84-5 HCAPLUS
CN Benzenepentanol, β-amino-α-[(dimethylamino)methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861899-85-6 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[(2-methylpropyl)amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861899-87-8 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[(phenylmethyl)amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861899-88-9 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[methyl(phenylmethyl)amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861899-90-3 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[(1-methylethyl)amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861899-91-4 HCAPLUS
CN Benzenepentanol, β-amino-α-[(cyclopropylamino)methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2),

(αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861899-92-5 HCAPLUS
CN Benzenepentanol, β-amino-α-[(ethylamino)methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861899-93-6 HCAPLUS
CN Benzenepentanol, β-amino-α-[(diethylamino)methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861899-94-7 HCAPLUS
CN Benzenepentanol, β-amino-α-[[(1,1-dimethylethyl)amino]methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861899-95-8 HCAPLUS
CN Benzenepentanol, β-amino-α-[(cyclopentylamino)methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861899-96-9 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[(propylamino)methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861899-97-0 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[methyl(1-methylethyl)amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861899-98-1 HCAPLUS
CN Benzenepentanol, β-amino-α-[[(1-ethylpropyl)amino]methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861899-99-2 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[(1-methylethyl)(phenylmethyl)amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861900-00-7 HCAPLUS
CN Benzenepentanol, β-amino-α-[[(cyclopropylmethyl)amino]methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861900-01-8 HCAPLUS
CN Acetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-02-9 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-α-[[(2-methoxyethyl)(1-methylethyl)amino]methyl]-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861900-03-0 HCAPLUS
CN Acetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-05-2 HCAPLUS
CN Acetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-06-3 HCAPLUS
CN Formamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-08-5 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[[(1S)-1-methylpropyl]amino]methyl]-, hydrochloride

(1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861900-09-6 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[[(1R)-1-methylpropyl]amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861900-10-9 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[[(1R)-1-methylpentyl]amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861900-11-0 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[[(1S)-1-methylpentyl]amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861900-12-1 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[[(1S)-1-methylhexyl]amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861900-15-4 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[[[(1R)-1-methylhexyl]amino]methyl]-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861900-17-6 HCAPLUS
CN Methanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-19-8 HCAPLUS
CN Benzamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-20-1 HCAPLUS

CN Benzamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methoxy-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-22-3 HCAPLUS
CN Benzenepentanol, β-amino-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-α-[(2-thiazolylamino)methyl]-, hydrochloride (1:1), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-23-4 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-24-5 HCAPLUS
CN Propanamide, 2-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861900-25-6 HCAPLUS
CN Acetamide, 2-[[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]amino]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861900-26-7 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methyl-, hydrochloride

(1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-28-9 HCAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-29-0 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N,2,2-trimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-30-3 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-ethyl-2,2-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-31-4 HCAPLUS
CN Butanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-ethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-32-5 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-chloro-2,2-dimethyl-,

hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-33-6 HCAPLUS
CN Acetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methoxy-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-34-7 HCAPLUS
CN Urea, N'-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N,N-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-35-8 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-hydroxy-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 861900-36-9 HCAPLUS
CN Methanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-37-0 HCAPLUS
CN Cyclopropanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-38-1 HCAPLUS
CN Cyclohexanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-39-2 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-40-5 HCAPLUS
CN Urea, N'-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N,N-diethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-41-6 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methoxy-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-42-7 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methoxy-, hydrochloride

(1:1), (2R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-43-8 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methoxy-, hydrochloride (1:1), (2S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-44-9 HCAPLUS
CN Benzenepentanol, β-amino-α-[[(1,1-dimethylpropyl)amino]methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861900-45-0 HCAPLUS
CN Benzenepentanol, β-amino-α-[[(1-ethyl-1-methylpropyl)amino]methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, hydrochloride (1:2), (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861900-46-1 HCAPLUS
CN Butanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-47-2 HCAPLUS
CN Pentanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-48-3 HCAPLUS
CN Hexanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-49-4 HCAPLUS
CN Cyclobutanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-50-7 HCAPLUS
CN Benzenesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA

INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-51-8 HCAPLUS
CN Propanamide, 2-(acetylamino)-N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-52-9 HCAPLUS
CN 2-Thiophenesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-53-0 HCAPLUS
CN Benzenemethanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-54-1 HCAPLUS
CN 1-Propanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-55-2 HCAPLUS
CN 1-Butanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-56-3 HCAPLUS
CN 2-Propanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-57-4 HCAPLUS
CN Cyclopropanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-58-5 HCAPLUS
CN Ethanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-59-6 HCAPLUS
CN Butanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-ethyl-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-60-9 HCAPLUS
CN Butanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-diethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-61-0 HCAPLUS
CN Cyclohexaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-62-1 HCAPLUS
CN Cyclopentaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-63-2 HCAPLUS
CN Cyclopropanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-phenyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-64-3 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-N-hydroxy-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 861900-65-4 HCAPLUS

CN Cyclobutanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-phenyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-66-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-phenyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-67-6 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-fluoro-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-68-7 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-hydroxy-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-72-3 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-chloro-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-73-4 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-chloro-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-74-5 HCAPLUS
CN Cyclobutanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-cyclohexyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-75-6 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-methoxy-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-76-7 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-methoxy-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-77-8 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α,4-trimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-78-9 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α,3-trimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-79-0 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-fluoro-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-80-3 HCAPLUS
CN 1-Piperidineacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861900-81-4 HCAPLUS
CN 4-Morpholineacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861900-82-5 HCAPLUS
CN Cyclobutanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-(4-chlorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-83-6 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-(cyclohexyloxy)-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-84-7 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-fluoro-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-85-8 HCAPLUS
CN 1H-Indole-3-acetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-86-9 HCAPLUS
CN 3-Pyridineacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861900-87-0 HCAPLUS
CN 2H-Pyran-4-acetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]tetrahydro-α,α-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-88-1 HCAPLUS
CN 2-Pyridineacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861900-89-2 HCAPLUS
CN 4-Piperidineacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 861900-90-5 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-methoxy-α-(trifluoromethyl)-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-91-6 HCAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-acetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1,2-dihydro-α,α-dimethyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

● 2 HCl

RN 861900-92-7 HCAPLUS
CN Cyclohexaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-hydroxy-α,α-dimethyl-, hydrochloride (1:1), cis- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-93-8 HCAPLUS
CN Cyclohexaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-hydroxy-α,α-dimethyl-, hydrochloride (1:1), trans- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-94-9 HCAPLUS
CN Cyclohexaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-methoxy-α,α-dimethyl-, hydrochloride (1:1), cis- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-95-0 HCAPLUS
CN Cyclohexaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-4-methoxy-α,α-dimethyl-, hydrochloride (1:1), trans- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-96-1 HCAPLUS
CN Cyclohexaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-methoxy-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-97-2 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-methoxy-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-98-3 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-methoxy-α-methyl-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861900-99-4 HCAPLUS
CN Benzenepropanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-methoxy-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861901-00-0 HCAPLUS
CN Butanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methoxy-, hydrochloride (1:1), (2R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 861901-02-2 HCAPLUS
CN 3-Piperidineacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, acetate (1:2) (CA INDEX NAME)

CM 1

CRN 861901-01-1
CMF C29 H51 N3 O5

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 861901-03-3 HCAPLUS
CN Cyclohexanepropanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-methoxy-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 861901-04-4 HCAPLUS
CN 3-Piperidineacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 861901-05-5 HCAPLUS
CN Benzenepropanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-methoxy-α-methyl-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 861922-82-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of diamino alcs. as renin inhibitors)
RN 861922-82-9 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



IT 861901-09-9P 861901-10-2P 861901-11-3P
861901-12-4P 861901-14-6P 861901-15-7P

861901-17-9P 861901-18-0P 861901-20-4P
1033706-96-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of diamino alcs. as renin inhibitors)

RN 861901-09-9 HCAPLUS
CN Carbamic acid, [(1S,3S)-1-[(1S)-2-(acetylmethylamino)-1-hydroxyethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 861901-10-2 HCAPLUS
CN Carbamic acid, [(1S,3S)-1-[(1S)-2-(acetylamino)-1-hydroxyethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 861901-11-3 HCAPLUS
CN Carbamic acid, N-[(1S,3S)-1-[(1S)-2-amino-1-hydroxyethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 861901-12-4 HCAPLUS
CN Carbamic acid, [(1S,3S)-1-[(1S)-2-azido-1-hydroxyethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 861901-14-6 HCAPLUS
CN Carbamic acid, [(1S,3S)-1-[(1S)-2-(benzoylamino)-1-hydroxyethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 861901-15-7 HCAPLUS
CN Carbamic acid, [(1S,3S)-1-[(1S)-2-[(2,2-dimethyl-1-oxopropyl)amino]-1-hydroxyethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 861901-17-9 HCAPLUS
CN Benzenepentanol, β-amino-α-[[(3-aminopropyl)amino]methyl]-4-methoxy-3-(3-methoxypropoxy)-δ-(1-methylethyl)-, (αS,βS,δS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 861901-18-0 HCAPLUS
CN Carbamic acid, [(1S,3S)-1-[(1S)-2-[(3-chloro-2,2-dimethyl-1-oxopropyl)amino]-1-hydroxyethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 861901-20-4 HCAPLUS
CN Carbamic acid, [(1S,3S)-1-[(1S)-1-hydroxy-2-[(1-methylethyl)(methylsulfonyl)amino]ethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 1033706-96-5 HCAPLUS
CN Carbamic acid, N-[(1S,3S)-1-[(1S)-2-[formyl(1-methylethyl)amino]-1-hydroxyethyl]-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methylpentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 1033573-82-8P 1033574-05-8P 1033697-59-4P
1033698-58-6P 1033700-50-3P 1033832-00-6P
1033834-11-5P 1033837-19-2P 1033841-57-4P
1033847-08-3P 1033858-41-1P 1033866-08-8P
1033873-57-2P 1033873-76-5P 1033877-74-5P
1033881-46-7P 1033883-99-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of diamino alcs. as renin inhibitors)
RN 1033573-82-8 HCAPLUS
CN Butanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methoxy-3,3-dimethyl-, hydrochloride (1:1), (2R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033574-05-8 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,3,3-trifluoro-2-methoxy-2-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033697-59-4 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,3,3-trifluoro-2-methoxy-2-methyl-, hydrochloride (1:1), (2R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033698-58-6 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3,3,3-trifluoro-2-methoxy-2-

methyl-, hydrochloride (1:1), (2S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033700-50-3 HCAPLUS
CN Cyclohexaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-methoxy-α-methyl-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033832-00-6 HCAPLUS
CN Cyclohexaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-3-hydroxy-α,α-dimethyl-, hydrochloride (1:1), (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033834-11-5 HCAPLUS
CN 1H-Imidazole-1-acetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 1033837-19-2 HCAPLUS
CN Propanamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-cyano-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033841-57-4 HCAPLUS
CN 3-Piperidineacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α,1-trimethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033847-08-3 HCAPLUS
CN Benzeneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-difluoro-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033858-41-1 HCAPLUS
CN 2H-Pyran-4-acetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2,2-difluorotetrahydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 1033866-08-8 HCAPLUS
CN Cyclohexaneacetamide, 3-(acetylamino)-N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α,α-dimethyl-, hydrochloride (1:1), (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1033873-57-2 HCAPLUS
CN 2-Propanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033873-76-5 HCAPLUS
CN Cyclohexanemethanesulfonamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-α-ethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033877-74-5 HCAPLUS
CN Cyclopentanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-methoxy-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033881-46-7 HCAPLUS
CN Cyclohexanecarboxamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-1-methoxy-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 1033883-99-6 HCAPLUS
CN Cyclohexaneacetamide, N-[(2S,3S,5S)-3-amino-2-hydroxy-5-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-6-methylheptyl]-2-hydroxy-α,α-dimethyl-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:472477 HCAPLUS
DOCUMENT NUMBER: 139:52753
TITLE: Preparation of substituted hydroxyethylamines as β-secretase inhibitors
INVENTOR(S): Tenbrink, Ruth; Maillard, Michel; Warpehoski, Martha
PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company
SOURCE: PCT Int. Appl., 306 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003050073	A1	20030619	WO 2002-US39050		20021206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2469622	A1	20030619	CA 2002-2469622		20021206
AU 2002360508	A1	20030623	AU 2002-360508		20021206
US 20040044072	A1	20040304	US 2002-313849		20021206
US 7312360	B2	20071225			
EP 1453788	A1	20040908	EP 2002-795769		20021206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
BR 2002014736	A	20041123	BR 2002-14736		20021206
JP 2005511735	T	20050428	JP 2003-551100		20021206
MX 2004005428	A	20041206	MX 2004-5428		20040604
US 20080096942	A1	20080424	US 2007-962454		20071221
PRIORITY APPLN. INFO.:			US 2001-338452P	P	20011206
			US 2002-313849	A1	20021206
			WO 2002-US39050	W	20021206

OTHER SOURCE(S): MARPAT 139:52753
GI



I



II

AB Title compds. I [E = bond, alkylene; RA = H, benzyloxycarbonyl; RD = H, alkoxycarbonyl; K = (un)substituted alkyl; A = aryl, cycloalkyl, heteroaryl, etc.; W = bond, SO0-2, (un)substituted amino; L = bond, absent, etc.; G = absent, alkyl, cycloalkyl, etc.; R2-3 = H, alkyl, aryl, etc.; RN = Ph naphthyl, tetralinyl, etc.; RC = heteroaryl, etc.] are prepared as β-secretase inhibitors. For instance, N-[(1S,2R)-1-[3-(cyclohexylmethyl)benzyl]-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl]acetamide (II) isolated as the HCl salt is prepared in several steps. The key intermediate in the synthesis is derived from the asym. hydrogenation of Me 2-[[(benzyloxy)carbonyl]amino]-3-(2-bromophenyl)acrylate (preparation given) to give the corresponding phenylalanine analog intermediate. I are useful for the treatment of Alzheimer's disease.

IT 546115-61-1P 546115-62-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted hydroxyethylamines as β-secretase inhibitors)

RN 546115-61-1 HCAPLUS

CN Carbamic acid, [(1S)-1-[(1R)-2-[[1-(3-bromophenyl)cyclopropyl]amino]-1-hydroxyethyl]-3-methyl-4-phenylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 546115-62-2 HCAPLUS
CN Acetamide, N-[(1S)-1-[(1R)-2-[[1-(3-bromophenyl)cyclopropyl]amino]-1-hydroxyethyl]-3-methyl-4-phenylbutyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:11099 HCAPLUS
DOCUMENT NUMBER: 136:69597
TITLE: Synthesis of hydrazide and α-alkoxyamide angiogenesis inhibitors
INVENTOR(S): Craig, Richard A.; Kawai, Megumi; Lynch, Linda M.; Patel, Jyoti R.; Sheppard, George S.; Wang, Jieyi; Yang, Fan; Ba-Maung, Nwe
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 78 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020002152	A1	20020103	US 2001-833917	20010412
US 20040167126	A1	20040826	US 2004-782502	20040219
US 6887863	B2	20050503		

PRIORITY APPLN. INFO.: US 2000-197262P P 20000414
US 2001-833917 A1 20010412

OTHER SOURCE(S): MARPAT 136:69597

GI



I



II



III

AB Title compds. I [R1 = alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, (heterocycle)alkyl, R5S-alkylene; R3 = H, alkyl, arylalkyl; R4 = NR6R7, OR8; R5 = alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl; R6-7 = H, alkanoyl, alkenyl, alkenyloxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, alkyl, alkylthioalkyl, aryl, arylalkanoyl, etc.; or R6-7 together are arylalkylidene; or R6-7 together with the nitrogen atom to which they are attached, form a heterocycle; R8 = H, alkanoylalkyl, alkenyl, alkoxycarbonylalkyl, alkyl, amidoalkyl, aryl, arylalkyl, etc.; R9-10 = H, alkyl, aryl] were prepared Over 450 synthetic examples were reported. For instance, (2R)-2-(Boc)amino-3-cyclohexylpropanoic acid was reduced to the corresponding alc. (PhMe, Red-Al, 0°C, room temperature 1 h) and oxidized to II (DMSO, Py•SO3, Et3N, room temperature 30 min). II was converted to the bisulfite addition product (H2O, NaHSO3, 5°C, 24 h) and reacted with KCN to give the α-hydroxy nitrile intermediate which was hydrolyzed to the carboxylic acid (12 N HCl, reflux, 21 h) and converted to III by condensation with benzylhydrazine (DCM/DMA, DIC, NMM, HOBt). Selected compds. I had IC50 < 0.1 μM for MetAP2. I are useful for inhibiting angiogenesis.

IT 369360-46-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; synthesis of hydrazide and α-alkoxyamide angiogenesis inhibitors)

RN 369360-46-3 HCAPLUS

CN Benzenehexanoic acid, β-amino-α-hydroxy-, 2-(3-chlorobenzoyl)hydrazide, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:780840 HCAPLUS
DOCUMENT NUMBER: 135:331197
TITLE: Synthesis of hydrazide and α-alkoxyamide angiogenesis inhibitors
INVENTOR(S): Craig, Richard A.; Kawai, Megumi; Lynch, Linda M.; Patel, Jyoti R.; Sheppard, George S.; Wang, Jieyi; Yang, Fan; Ba-Maung, Nwe Y.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079157	A1	20011025	WO 2001-US12274	20010413
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2406442	A1	20011025	CA 2001-2406442	20010413
EP 1272456	A1	20030108	EP 2001-925029	20010413
EP 1272456	B1	20041027		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001007204	A	20040225	BR 2001-7204	20010413
JP 2004509063	T	20040325	JP 2001-576759	20010413
AT 280753	T	20041115	AT 2001-925029	20010413
PT 1272456	T	20050228	PT 2001-925029	20010413
ES 2231475	T3	20050516	ES 2001-925029	20010413
MX 2002010082	A	20030425	MX 2002-10082	20021011
HK 1053825	A1	20050819	HK 2003-104469	20030620
PRIORITY APPLN. INFO.:			US 2000-549995 A	20000414
			US 2001-813008 A	20010321
			WO 2001-US12274 W	20010413

OTHER SOURCE(S): MARPAT 135:331197
GI



I



II



III

AB Title compds. I [R1 = alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, (heterocycle)alkyl, R5S-alkylene; R3 = H, alkyl, arylalkyl; R4 = NR6R7, OR8; R5 = alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl; R6-7 = H, alkanoyl, alkenyl, alkenyloxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, alkyl, alkylthioalkyl, aryl, arylalkanoyl, etc.; or R6-7 together are arylalkylidene; or R6-7 together with the nitrogen atom to which they are attached, form a heterocycle; R8 = H, alkanoylalkyl, alkenyl, alkoxycarbonylalkyl, alkyl, amidoalkyl, aryl, arylalkyl, etc.; R9-10 = H, alkyl, aryl] were prepared Over 450 synthetic examples were reported. For instance, (2R)-2-(Boc)amino-3-cyclohexylpropanoic acid was reduced to the corresponding alc. (PhMe, Red-Al, 0°C, room temperature 1 h) and oxidized to II (DMSO, Py•SO3, Et3N, room temperature 30 min). II was converted to the bisulfite addition product (H2O, NaHSO3, 5°C, 24 h) and reacted with KCN to give the α-hydroxy nitrile intermediate which was hydrolyzed to the carboxylic acid (12 N HCl, reflux, 21 h) and converted to III by condensation with benzylhydrazine (DCM/DMA, DIC, NMM, HOBt). Selected compds. I had IC50 < 0.1 μM for MetAP2. I are useful for inhibiting angiogenesis.

IT 369360-46-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; synthesis of hydrazide and α-alkoxyamide angiogenesis inhibitors)

RN 369360-46-3 HCAPLUS

CN Benzenehexanoic acid, β-amino-α-hydroxy-, 2-(3-chlorobenzoyl)hydrazide, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:604555 HCAPLUS
DOCUMENT NUMBER: 125:301563
ORIGINAL REFERENCE NO.: 125:56459a,56462a
TITLE: Design and synthesis of novel, pseudo C2 symmetric inhibitors of HIV protease
AUTHOR(S): Hanessian, Stephen; Devasthale, Patrick V.
CORPORATE SOURCE: Department Chemistry, Universite Montreal, Montreal, QC, H3C 3J7, Can.
SOURCE: Bioorganic & Medicinal Chemistry Letters (1996), 6(18), 2201-2206
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A novel series of chain-extended, pseudo C2 sym. 1,5-diamino alc. analogs was designed and synthesized using an efficient nitroaldol condensation mediated by triethylsilyl triflate and TBAF.xH2O. Thus, derivs. of the nitro compound I, e.g., II and III were prepared Prototypical acyclic compds. harboring a central spirolactam or a nitro group, and amide variants of an off-center 1,5-diamino alc. analog were synthesized and their activities against HIV protease evaluated.

IT 182937-11-7P 182937-20-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(design and synthesis of pseudo C2 sym. inhibitors of HIV protease)

RN 182937-11-7 HCAPLUS

CN Benzenepentanol, δ-[bis(phenylmethyl)amino]-α-[1-[bis(phenylmethyl)amino]-2-phenylethyl]-β-nitro- (9CI) (CA INDEX NAME)



RN 182937-20-8 HCAPLUS
CN Carbamic acid, [2-hydroxy-3-nitro-1,5-bis(phenylmethyl)-1,5-pentanediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	115.83	490.69
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-13.94	-13.94

STN INTERNATIONAL LOGOFF AT 09:58:07 ON 26 MAR 2009